Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
1  
 Confidential  
May  not be used,  divulged,  published  or otherwise  disclosed  without  the consent  of Magenta   
 
Magenta Therapeutics  
MGTA-456 
 
 
 
 
 
 
CLINICAL TRIAL PROTOCOL  IMD -001 
A Phase 2, Single -arm, Open -label Study to Evaluate the Safety and Efficacy  
of MGTA -456 in Patients with Inherited Metabolic Disorders (IMD)  
Undergoing Hematopoietic  Stem  Cell (HSC)  Transplantation (HSCT)  
 
 
     
 
 
Sponsor:  Magenta  Therapeutics,  Inc. (Magenta)  
Document  Type:  Amended  Protocol  
IND Number:  16729  
Version:  08 
Development  Phase:  2 
Document  Status:  FINAL  
Date:  10/Jan/2020  
 
   
 
 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
5  
 5.2 Treatment  Arms  ...............................................................................................................43 
5.3 Permitted  Dose  Adjustments and Interruptions of Study Treatment  ...............................43 
5.4 Treatment  Assignment .....................................................................................................43 
5.5 Treatment  Blinding ..........................................................................................................43 
5.6 Treatment  Exposure .........................................................................................................43 
5.7 Recommended  Treatment of Adverse Events .................................................................43 
5.7.1 Slow Engraftment/Graft  Failure  ......................................................................................44 
5.7.2 Anemia  ............................................................................................................................44 
5.7.3 Thrombocytopenia ...........................................................................................................44 
5.7.4 Nutrition  ..........................................................................................................................44 
5.7.5 Acute Graft Versus Host Disease  ....................................................................................44 
5.7.6 Infusional Reaction  ..........................................................................................................44 
5.7.7 Engraftment Syndrome/Transfusion Related Acute Lung Injury (TRA LI) ....................45 
5.7.8 Autoimmune Cytopenia ...................................................................................................45 
5.8 Concomitant Treatment  ...................................................................................................45 
5.8.1 Pre-medications  ...............................................................................................................46 
5.8.2 Stem  Cell Engraftment Enhancement  .............................................................................46 
5.8.3 Anti-Oxidants and Anti- Inflammatories  ..........................................................................46 
6. DISCONTINUATION AND STUDY COMPLETION  .................................................47 
6.1 Discontinuation of Study .................................................................................................47 
6.2 Study Com
pletion and Post-Study Treatment .................................................................47 
6.2.1 Lost to Follow-up ............................................................................................................47 
6.3 Withdrawal  of Consent ....................................................................................................47 
6.4 Study Stopping Rules  ......................................................................................................47 
6.5 Early  Study Termination .................................................................................................49 
7. PROCEDURES  AND ASSESSMENTS  .........................................................................50 
7.1 Informed  Consent Procedures .........................................................................................54 
7.2 Patient  Demographics and Other Baseline Characteristics  .............................................54 
7.2.1 Lansky Performance  Status  .............................................................................................54 
7.2.2 Pre-existing  Anti -HLA Donor- Specific  Antibodies ........................................................55 
7.2.3 Human  Leukocyte Antigen Typing .................................................................................55 
7.2.4 Chest  X-ray ......................................................................................................................55 
7.2.5  .......................................................................................................................55 

Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
6  
 7.3 Efficacy/Pharmacodynamics  ...........................................................................................56 
7.3.1 Assessment  of Engraftment and Graft Failure ................................................................56 
7.3.2 Chimerism Studies  ...........................................................................................................56 
7.3.3  .........................................................................56 
7.4 Safety  ...............................................................................................................................57 
7.4.1 Physical  Examination  ......................................................................................................57 
7.4.2 Vital Signs  .......................................................................................................................57 
7.4.3 Height and Head Circumference .....................................................................................57 
7.4.4 Laboratory Evaluations ...................................................................................................57 
7.4.4.1 Hematology .....................................................................................................................58 
7.4.4.2 Clinical Chemistry  ...........................................................................................................58 
7.4.4.3 Viral  Testing/Infection Surveillance ...............................................................................58 
7.4.5 Electrocardiogram  and Echocardiogram  .........................................................................58 
7.4.6 Pregnancy  Testing  ...........................................................................................................58 
7.4.7 Pulmonary Function Tests (PFT) ....................................................................................58 
7.4.8 Graft  Versus Host Disease  Assessments .........................................................................59 
7.4.9 Survival Information .......................................................................................................59 
7.4.10 Assessment  of Infusional Toxicities  ................................................................................59 
7.4.11 Assessment  of Infectious Events After Transplantation .................................................59 
7.4.12 Transfusion Support ........................................................................................................59 
7.5 Pharmacokinetics  .............................................................................................................59 
7.6 Ot
her Assessments ...........................................................................................................60 
7.6.1  .............................................................60 
7.6.2  .................................................................................................................60 
7.6.3  .........................................................................................60 
7.6.4  ......................................................61 
7.6.5  ..............................................................................61 
7.6.5.1  .................................................................61 
7.6.5.2  ..............................................................................................61 
7.6.5.3  .............................................................61 
7.6.5.4  ...................................................................................................61 
7.6.5.5  ......................................................................................62 
7.6.5.6  ...........................................................................................62 

Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
7  
 8. SAFETY  MONITORING  ...............................................................................................63 
8.1 Adverse Events ................................................................................................................63 
8.1.1 Non-Serious AE  Documentation .....................................................................................64 
8.2 Serious Adverse Event Reporting ....................................................................................65 
8.2.1 Definition  of a Serious Adverse Event ............................................................................65 
8.2.2 SAE  Reporting .................................................................................................................66 
8.3 Pregnancy  Reporting .......................................................................................................67 
8.4 Prospective Suicidality  Assessment  ................................................................................68 
8.5 Early  Phase Safety  Monitoring ........................................................................................68 
9. DATA REVIEW  AND DATABASE  MANAGEMENT  ................................................69 
9.1 Site Monitoring ................................................................................................................69 
9.2 Data Collection  ................................................................................................................69 
9.3 Database  Management  and Quality Control ....................................................................69 
9.4 Data Monitoring Committee  ............................................................................................70 
10. DATA ANALYSIS  .........................................................................................................71 
10.1 Analysis Sets  ...................................................................................................................71 
10.2 Patient  Demographics and  Other  Baseline Characteristics  .............................................71 
10.3 Treatments - Study Drug, Rescue Medication, Other Concomitant Therapies, 
Compliance ......................................................................................................................71 
10.4 Analysis of the Prima ry Variable(s)  ................................................................................71 
10.4.1 Endpoints .........................................................................................................................71 
10.4.2 Statistical Model, Hypothesis, and Methods of Analysis ................................................71 
10.4.3 Handling of Missing Values,  Censoring, and Discontinuations ......................................71 
10.4.4 Supportive Analyses  ........................................................................................................72 
10.5 Analysis of Secondary and Exploratory Variables  ..........................................................72 
10.5.1 Secondary  and Exploratory Endpoints ............................................................................72 
10.5.2 Safety  ...............................................................................................................................72 
10.5.2.1 Vital Signs .......................................................................................................................72 
10.5.2.2 ECG  Evaluations .............................................................................................................72 
10.5.2.3 Clinical Laboratory Evaluations ......................................................................................72 
10.5.2.4 Adverse Events ................................................................................................................72 
10.5.2.5 Concomitant Medications/Significant Non-Drug Therapies  ...........................................73 
10.5.2.6 Other  Safety  Evaluations .................................................................................................73 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
10  
 LIST  OF ABBREVIATIONS  
 
Abbreviation  Definition  
ABW  actual  body weight 
AE adverse  event 
aGVHD  acute graft versus host disease  
AHR  aryl hydrocarbon receptor  
AIBW  adjusted  ideal  body  weight  
AIC autoimmune  cytopenia 
ALC  absolute lymphocyte count 
ALT  alanine aminotransferase  
ALD Adrenoleukodystrophy 
ANC  absolute  neutrophil count  
AST  aspartate  aminotransferase  
ATG  antithymocyte  globulin  
AUC cum cumulative  area under the plasma  concentration -time curve 
AUC  area under the plasma  concentration- time curve  
AUC ∞ area under the  plasma  concentration- time curve  from  time zero  to infinity  
AUC last area under the plasma concentration -time curve from time zero to time of last  
measurable concentration 
BLA  Biologics  License Application  
BMT  bone  marrow  transplant  
BU busulfan  
BUN  blood  urea nitrogen  
cALD  cerebral  adrenoleukodystrophy  
CBU  cord blood unit 
CFR Code of Federal  Regulations  
cGVHD  chronic graft  versus host disease  
CLIA  Clinical Laboratory Improvement  Amendment 
Cmax maximum  observed  concentration  
CMV Cytomegalovirus 
CNS  central nervous  system  
CsA cyclosporine  A 
CSF cerebrospinal  fluid 
CTCAE  Common Toxicity  Criteria  Adverse Event  
CY cyclophosphamide 
DNA  deoxyribonucleic  acid 
DMC  data monitoring  committee  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
11  
  
Abbreviation  Definition  
DUCBT  double umbilical cord blood transplantation  
ECG  Electrocardiogram  
eCRF  electronic case  report  form  
ERT  enzyme  replacement  therapy  
EBV  Epstein -Barr virus  
FDA Food and Drug  Administration  
GAG  Glycosaminoglycan 
GCP  Good Clinical Practice 
G-CSF granulocyte-colony stimulating  factor  
GGT  gamma -glutamyl transferase  
GLD  globoid  cell leukodystrophy  
GM-CSF macrophage -colony  stimulating  factor  
GVHD  graft  versus  host disease  
HR hazard  ratio 
HBcAb  hepatitis  B core antibody 
HBsAg  hepatitis  B surface  antigen 
hCG  human chorionic gonadotropin 
HCV  hepatitis  C virus  
HIV human  immunodeficiency  virus  
HLA human leukocyte  antigen  
HNA  human neutrophil antigen 
HSC  hematopoietic  stem  cells 
HSCT  hematopoietic  stem  cell transplantation 
HSV herpes simplex  virus 
HTLV1/2  human T cell lymphotropic  virus  ½ 
IB Investigator’s  Brochure  
IBW  ideal  body  weight  
ICF informed  consent  form  
ICH International Council for Harmonisation  
IEC Independent Ethics  Committee  
Ig immunoglobulin 
IMD  inherited metabolic  disorders 
IRB institutional  review  board  
IUD intrauterine  device  
IUS intrauterine  system  
IV intravenous 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
12  
  
Abbreviation  Definition  
IVIg  intravenous immunoglobulin 
LDH lactate  dehydrogenase 
LFT liver function test  
LLOQ  lower  limit  of quantification  
LMW  low molecular  weight  
LVEF left ventricular  ejection  fraction  
MAC  myeloablative  conditioning 
Magenta  Magenta Therapeutics,  Inc. 
MFI mean  fluorescence intensity  
MedDRA  medical  dictionary for regulatory activities  
MLD  metachromatic  leukodystrophy  
MMF  mycophenolate  mofetil  
MP Methylprednisolone  
MRI  magnetic resonance imaging  
MPS- HAQ  Mucopolysaccharidosis- Health  Assessment  Questionnaire  
MPS- IH mucopolysaccharidosis- IH 
MSD  matched  sibling donor 
NFS neurological function score 
NMAC  non-myeloablative  conditioning  
NOAEL  no observed adverse effect  level  
NRE  non-reducing-end 
PES pre-engraftment  syndrome  
PFT pulmonary function test 
PK pharmacokinetic 
PMBC peripheral blood mononuclear cells 
PO oral(ly)  (per oral) 
SAB  single  antigen  bead 
SAE  serious adverse event 
SOP standard  operating procedure  
SR-1 StemRegenin -1 
SUCBT  single  umbilical  cord  blood transplantation  
TEAE treatment -emergent  adverse  events  
TID three  times  a day  
TRALI  transfusion -related  acute lung injury 
TNC  total nucleated  cell 
TREC  T cell receptor  excision circles 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
13  
  
Abbreviation  Definition  
TRSALI  transfusion -related  acute lung injury 
TRM  transplant -related  mortality  
UCB  umbilical cord blood 
UCBT  umbilical  cord blood  transplant  
ULN  upper  limit of  normal  
US United  States  
VLCFA  very long chain fatty acids  
WHO World  Health  Organization 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
14  
 SYNOPSIS  
 
Protocol  number  IMD -001 
Title  A Phase 2, single -arm, open -label study to evaluate the safety and efficacy of MGTA -456 
in patients with selected inherited metabolic disorders (IMD) undergoing hematopoietic  
stem cell  (HSC)  transplantation  (HSCT) 
Brief  title MGTA -456 in patients  with inherited metabolic  disorders  undergoing HSCT  
Sponsor  and Clinical 
Phase  Magenta  Therapeutics,  Inc.; Phase  2 
Intervention  type Intravenous  (IV) administration  of HSC  therapy  product  
Study  type Interventional  
Purpose  and rationale  To evaluate the safety and efficacy of MGTA -456 after myeloablative conditioning to 
induce rapid and sustained hematopoietic engraftment with replacement of the specific  
protein product missing or defective in the patient with an IMD. The study aims to  
enhance the efficacy of umbilical cord blood (UCB) transplantation (UCBT), to preserve  
neurodevelopment in patients with selected IMDs. Since MGTA -456 offers increased  
numbers of HSCs over standard UCB, it is expected to reduce the risks of prolonged  
neutrope nia and thrombocytopenia and graft failure, and potentially transplant -related  
mortality  (TRM).  
Primary  Objective(s)  To evaluate the effect of MGTA -456 on the rate and incidence of neutrophil recovery in 
patients  with IMD undergoing  HSCT  
Secondary  Objectives  • To evaluate the safety  of MGTA -456 in patients  with IMD  undergoing HSCT  
• To characterize engraftment following transplantation with MGTA -456 and to 
evaluate the effect of MGTA -456 on chimerism in the CD3 and CD33/66 (or  
CD15) hematopoietic compartments  
• To assess the incidence of acute and chronic  graft  versus  host disease  (GVHD) 
• To assess transplant -related  mortality (the  incidence of TRM)  
Study  design  This is a Phase 2, open -label, single -arm study in which patients with IMDs will receive  
MGTA -456 as a stand- alone HSC graft after MAC. Approximately 12 patients with IMD  
will be enrolled and followed for  one year,  with the option to include  up to approximately  
15 additional patients  in an expansion cohort.  
Population  Children age < 2.5 years with Hurler syndrome, age 2 -17 years with cerebral  
adrenoleukodystrophy (cALD), age <16 years with metachromatic leukodystrophy  
(MLD)  and age ≤ 10 years  with globoid  cell leukodystrophy (GLD)  (also  referred  to as 
Krabbe).  
Inclusio n criteria  Male and female, age < 2.5 years with Hurler syndrome, age 2 -17 years with cerebral  
adrenoleukodystrophy (cALD), age < 16 years with metachromatic leukodystrophy  
(MLD)  and age ≤ 10 years  with globoid  cell leukodystrophy (GLD)  (also  referred  to as 
Krabbe).  
Diagnosed with one  of the  following IMDs:  
• Hurler  syndrome  (Mucopolysaccharidosis  I Hurler  [MPS- IH]) 
• MLD:  asymptomatic  late-infantile,  or asymptomatic/minimally  symptomatic  
juvenile  onset patients  
• GLD,  or early  attenuated  disease  
• cALD with Loes  score  ≤10, and with neurologic  functional  score  (NFS)  ≤1. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
15  
  
 Patient  must  have  a minimum  life expectancy  of 6 months  in the judgment  of the 
Investigator.  
Recipients  must meet  the following criteria: 
• Lansky score  ≥50%  
• Renal:  serum creatinine ≤2.5 × upper  limit of normal  (ULN)  corrected  for age 
• Hepatic: total bilirubin and alanine aminotransferase (ALT) ≤3 × ULN corrected  
for age  
• Pulmonary function: oxygen saturation ≥92% without an oxygen requirement;  
an exception may be made as documented in the medical record for patients  
with abnormal sleep  studies  (such  as Hurler  patients)  
• Cardiac: left ventricular ejection fraction ≥30.  
Requi red graft characteristics:  
• The UCB unit must be at least 6/8 HLA -A, HLA- B, HLA -C, and HLA -DRB1  
matched with the recipient at the allele level. This is based upon a recent  
publication which showed that allele -level matching at HLA -A, HLA- B, HLA -C 
and HLA -DRB1 between the UCB unit and its recipient is associated with best 
survival and lowest occurrence of graft failure in children with non- malignant  
diseases.  
• The UCB units mu st come from a qualified UCB bank(s) per institutional  
standard operating procedures (SOPs). Any matched unit not from a qualified 
UCB bank must be pre -approved for use by the Sponsor. If the UCB unit is  
“unlicensed” (most commonly based on location [e.g.,  European countries], 
testing by non- CLIA (Clinical Laboratory Improvement Amendment) approved 
laboratories,  or collection  before  May 25, 2005),  the Sponsor  will make the final 
decision on patient eligibility based on the reason why the UCB unit is  
unlicen sed 
• The minimal total nucleated cell  (TNC) count  for the selected  UCB unit is to be  
1.0 ×  107/kg of the recipient’s  body weight  
• In a case where  there  is a better  HLA- matched UCB  unit with a  lower  cell dose,  
it may be selected over  a less well- matched unit  with a  higher cell  dose 
• The patient must not have donor -specific anti -HLA antibodies considering HLA  
A, B, C, DRB1,  DQ and DP  (Mean  Fluorescence Intensity  [MF]I  >1000).  
• A suitable  back -up HSC  source  (UCB unit or unaffected  haploidentical donor)  
must  be available.  
• Cord  blood grafts  require genetic  testing and/or  demonstration  of enzyme  
activity for patients with Hurler syndrome, MLD or GLD and are tested for very  
long chain fatty acids (VLCFA) to confirm there is no evidence of VLCFA  
consistent  with ALD 
Exclusion  criteria  • Availability of 8/8 HLA -matched related donor who is not a carrier of the same 
genetic defect.  
• Active  infection  at Screening  (defined  as requiring  parenteral  antibiotics  because  
of persistent changes consistent with infection based on imaging studies and/or 
positive cultures) including active infection with Aspergillus or other fungus  
within 30 days prior to screening, or severe concomitant diseases which in the  
judgment of the Investigator would lead to the patient’s inability to tolerate the  
protocol  specified conditioning  regimen.  
• Prior  myeloablative conditioning.  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
18  
 1. INTRODUCTION 
1.1 Background  
1.1.1 Inherited  Metabolic Disease  
Inherited metabolic diseases (IMD), including cerebral adrenoleukodystrophy (cALD), globoid 
cell leukodystrophy (GLD or Krabbe), metachromatic leukodystrophy (MLD), and Hurler 
syndrome are a group of rare, inherited disorders that result in a progressive loss of neuromotor 
and cognitive abilities.  Untreated,  these disorders are progressive and lethal.  Enzyme 
replacement of lysosomal disorders cannot correct the central nervous system (CNS) defects due to lack of penetration of the blood- brain -barrier. The o nly effective neurologic therapy for MLD, 
GLD, cALD, and Hurler syndrome is allogeneic hematopoietic stem cell transplantation (HSCT), after which immature cells of hematopoietic origin migrate to tissues, including the CNS  
(Orchard  et al 2007; P rasad  et al 2008). 
In cALD, mutations in the ABCD1 gene cause a defect in peroxisome membrane transport and  
lead to accumulation of VLCFA. High levels of VLCFA in turn cause inflammation and demyelination within the CNS white matter resulting in progressive disease. Microglia derived  
from allogeneic bone marrow progenitors are hypothesized to ameliorate the defe ct by  
processing VLCFA. One general mechanism known as cross-correction has been shown in Hurler  syndrome where microglia  capable of providing the α -L-iduronidase enzyme to  the CNS  
of Hurler patients supply the defective enzyme and serve as a permanent source of cellular  
enzyme replacement ( Krivit et al 1995). This same mechanism is thought to provide clinical 
benefit  to those with early and/or attenuated MLD and GLD. 
While allogeneic HSCT is considered the standard of care for these diseases, the morbidity and 
mortality of transplantation are significant, with peri- transplant mortality reported as 20% to 
30% ( Prasad et al 2008; B oelens et al 2013). Transplant- related mortality (TRM) is in part 
caused by the conditioning regimen, which traditionally has included myeloablative doses of 
chemotherapy and/or radiation and was independent of the specific indication. Reducing TRM is a high priority in this patient population. 
Most of the mortality in patients with IMD occurs within the first 6 months of HSCT, most often  
secondary to transplant- related complications. The best outcomes are achieved in patients  
receiving a genotypic-identical sibling donor bone marrow transplant (BMT) or a human 
leukocyte antigen (HLA)-matched, unrelated UCB transplant (UCBT) prior to the onset of 
irreversible  neurologic complications ( Boelens et al 2013). 
UCB  has become a preferred choice for patients  lacking a HLA matched  related donor due to  its 
rapid availability and permissiveness for HLA allele mismatching. In one center, an outcome study of 159 patients with IMDs undergoing UCBT ( Prasad et al 2008; F igure 1 ), overall 
survival was 71.8% at 1 year. Median time to neutrophil engraftment was 22 days with a  
cumulative incidence by Day 42 of 87%. Platelet engraftment occurred in a median of 87 days  
with a cumulative incidence of 71% at 180 days. Factors significantly affecting neutrophil engraftment included HLA match of at least 5/6 (hazard ratio [HR] 1.4, p=0.04), higher CD34+ cell dose (HR 1.76, p<0.01) and higher TNC (HR 1.78, p<0.01) ( Figure 1). In terms of GVHD , 
the incidence of grade II -IV acute graft versus host disease (aGVHD) was approximately 41%  
and grade II -IV was 10.2%. Chronic GVHD was  observed in 20.9% at 1 year.  Graft failure  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
19  
 occurred in 8.2% of patients; however additional studies have reported higher rates of  
approximately 20%  (Miller et al  2011; Ma rtin et al 2006; B eam et  al 2007). 
Study  IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
20  
  
Figure 1: Impact  of Graft  Characteristics  on the Probability of Engraftment  and Overall  Survival 
 
 
MSD=matched sibling donor; CB=cord blood; MUD=matched unrelated donor; MMUD=mismatched unrelated donor; OS=overall survival; TNC=total 
nucleated cell. Event -free survival is  defined  as alive with  donor -derived engraftment.  

Study  IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
21  
  
Note: Probability plots are shown for the each of the 4 quartiles. Panels A, E, and I depict the impact of cryopreserved TNCs  (x 107/kg recipient weight) on  
neutrophil engraftment, platelet engraftment, and OS, respectively. Panels B, F, and J depict the impact of infused TNCs ( x 107/kg recipient weight) on  
neutrophil engraftment, platelet engraftment, and OS, respectively. Panels C, G, and K depict the impact  of infused CD34 cells ( x 105/kg recipient weight) on  
neutrophil engraftment, platelet engraftment, and OS, respectively. Panels D, H, and L depict the impact of infused CFUs ( x 104/kg recipient weight) on 
neutrophil  engraftment,  platelet  engraftment, and  OS, respectively.  P values  are shown with each plot  for the quartile  analysis.  
Source:  Prasad et al 2018  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
25  
 In the double UCB (DUCBT) cohort of CHSC835X2201, the incidence of neutrophil recovery 
was 100% for both adult (n=15) and pediatric patients (n=3) occurring at a median of 16 days  
(6-30) and  7 days, respectively. The incidence of platelet  recovery was  73%  and 67%  for adult 
and pediatric patients at  a median of 59 days for adults (range, 28 to 108 days) and 22 and 
59 days for the 2 of 3 pediatric patients. Of the 18 patients, 1 had transient hypotension 4 hours 
after the infusion of MGTA-456 which was subsequently demonstrated to be due to an occult 
bacterial contamination of the MGTA -456 product. Otherwise, no infusional toxicities were  
noted and no other adverse effects were attributed to MGTA- 456. Grade III aGVHD was  
diagnosed in 3 adult patients and Grade IV aGVHD was reported in one patient. None of the pediatric patients developed Grade III or IV aGVHD. The adverse event (AE) profiles between  
day 0 and day 30 were comparable to those commonly observed after UCB transplantation. In addition, no patient had late graft failure with the longest follow-up of 687+ days. In terms of other transplant outcomes, overall survival for adult and pediatric patients combined (10/18, 55.6%) was similar to the historical cohort. Primary causes of death were acute GVHD (n=4),  
alveolar  hemorrhage (n=2), idiopathic pneumonia (n=1),  and relapse (n= 1). 
In the single UCB  (SUCBT)  cohort of CHSC835X2201 (n=9), there  were 8 adults and  
1 pediatric patient.  The incidence of neutrophil recovery was 100%, at a median of 17 days  
(range:  7-32 days) for the adults and  day 8 for the single pediatric  patient.  For adults transplanted 
with MGTA-456 as a stand -alone product, the incidence of platelet recovery  was 63%  at 
Day 180 at a median of 50.5 days (range 42 to 181 days). The single pediatric patient had platelet recovery  after 97 days. 
The primary endpoint of the SUCBT clinical trial was to determine the safety of MGTA -456. 
There were no infusional toxicities noted within the first 24 hours after transplant and no other 
adverse effects were observed that could be attributed to the product infusion. In addition, no 
patient had late graft failure within the follow -up period. In terms of other transplant outcomes, 
Grade II-IV and Grade III -IV aGVHD  occurred  in 4 and  2 of 9 patients, respectively,  at a median  
of 34.5 days after transplant. Thus far, TRM has been low with 1 of 9 dying due to non- disease  
related  reasons. 
The median follow-up is 6 months (range: 1 to 38 days). At time of the last data cut off, 6 of 9  
were alive  with deaths due to relapse (n=2),  alveolar  hemorrhage (n=1).  
Overall, the median time to engraftment for the 27 patients in the study was 14 days (range 6 to 
32 days), which compares favorably with the time to neutrophil recovery reported for DUCBT 
patients at the University of Minnesota receiving the same conditioning regimen and GVHD 
immune prophylaxis, which was 26 days ( Brunstein et al 2010). The pace of hematopoietic 
recovery  was remarkably  rapid  in patients  where MGTA-456 with a  CD34  cell dose 
>10 million/kg could be administered. Similarly, the fraction of patients achieving platelet 
recovery was greater in patients rec eiving MGTA-456 and the pace of platelet recovery was 
accelerated relative to DUCBT patients (for details see the published results of the DUCBT  
patients enrolled in this study ( Wagner et al 2 016). Of note, the length of hospitalization was 
significantly reduced in recipients of MGTA-456 (median of 27 days compared to 46 days in the control population, p<0.001). 
Study CHSC835X2202 was a single-arm, open-label study evaluating the safety and tol erability  
of MGTA -456 as single stand- alone graft (SUBCT) in patients with hematologic malignancies  
undergoing a reduced dose conditioning to minimize TRM  in an older population or those with 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
29  
 2. OBJECTIVES AND ENDPOINTS  
 
 Objective  Endpoint  
Primary  To evaluate the effect of 
MGTA-456 on the rate of neutrophil recovery in 
patients with IMD undergoing HSCT  Incidence of engraftment with  
MGTA-456, engraftment defined as achieving an  
absolute neutrophil count (ANC)  ≥0.5 ×  10
9/L for  
3 consecutive days 
Time to neutrophil recovery  
defined as the first  day of 
3 consecutive days with an  
ANC  ≥0.5 × 109/L 
Secondary  To evaluate the safety of  
MGTA-456 in patients with 
IMD  undergoing HSCT Incidence of  infusion 
toxicities (incidence of  
MGTA -456-related  AEs that 
  limit  MGTA -456 
  administration)  
  Incidence of  TEAEs  
 To characterize engraftment  
following transplantation with 
MGTA-456 and to evaluate 
the effect of MGTA -456 on 
chimerism in the CD3 and CD33/66 (or CD15) 
hematopoietic  compartments  Incidence of late hematological graft failure  
defined as meeting 1 of the 
following 3 criteria:  
(1) <5% donor whole blood 
or myeloid  chimerism  in 
peripheral  blood or  bone  
  marrow  beyond Day  42 
  post-transplant  in patients  
  with prior  hematopoietic  
  recovery  with ≥5%  donor  
  cells by Day 42  
  post-transplant;  (2) Sustained  
  decline  in the ANC  to 
  <500/mm3 for 3 consecutive  
  measurements  on different  
  days,  unresponsive  to growth  
  factor  therapy  after initial  
  hematopoietic  recovery  by 
  Day 42; (3) Subsequent  bone  
  marrow  aplasia  identified  
  after initial  hematopoietic  
  recovery  by Day 42  
  Number  of days with 
  neutropenia  from  the day  of 
  transplant  through  Day 42  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
32  
 3. INVESTIGATIONAL  PLAN  
3.1 Study  Design  
This is a Phase 2, open-label, single- arm study in which patients with IMD will receive  
MGTA-456 as  a stand -alone HSC graft  after  MAC.  Approximately 12 patients will be enrolled  
into 1 of 2 sequential cohorts, with the option to include up to approximately 15 additional 
patients  in an expansion cohort following dosing of Cohort 2. Cohort 1 will comprise 
approximately 6 patients  who will receive MGTA-456 fresh  expanded CD34+  cells and Cohort 2 
will comprise approximately 6 patients who will receive MGTA -456 cryopreserved expanded 
CD34+ cells. Up to approximately 15 additional patients may be included in an expansion cohort following dosing of Cohort 2; these patients will receive MG TA-456 cryopreserved expanded 
CD34+ cells. All patients will be followed up to the end of study visit at 1 year after  
post-transplant. The  design is presented  in Figure 3. 
Figure 3: Study  Design  
 
Note: Up to approximately 15 additional patients may be included in the study following dosing of Cohort 2 and will receive  
cryopreserved  MGTA -456 product.  
 
 
For each patient in Cohort 1 (see Section 3.1.1) and Cohort 2 (see Section 3 .1.2), the study will 
consist of an approximately 50-day screening period (Day -60 to Day - 10). The patient must 
meet all eligibility criteria before the expansion culture will be initiated. Following MGTA -456 
manufacturing, patients will be admitted to begin the transplant conditioning regimen (Day -9 to 
Day - 1 [see Section 5.1.2 for details]). The day of MGTA-456 administration will be considered 
Day 0 and will consist of the infusion of the expanded CD34+ fraction followed by the infusion of the CD34-depleted fraction of the cord blood unit (CBU). Infusional toxicity will be assessed  
within 48 hours after transplant. Each patient will remain hospitalized until neutrophil recovery is achieved (refer to Section 7.3.1 for neutrophil recovery definition). The patient will be monitored with protocol -specific procedures for 1 year following transplant to assess 
engraftment, graft failure, and late hematological graft failure (refer to Section 7.3.1 for definitions) and other study endpoints. 
Any patient  (or guardian) withdrawing their  consent or any  patient  withdrawn  because of an 
event unrelated to the study, at any time during the study, will be replaced to ensure 
approximately 6 evaluable patients in each  cohort. 
After  1 year,  patients  may  be transferred  to a separate long- term follow up study, if  eligible  and 
willing  (after signature  of the specific study informed consent form [ICF]). 

Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
34  
 For both cohorts, starting  on Day  0 of the study, 2 therapeutic cell  preparations will be infused 
sequentially  in the followin g order. 
1. A minimal  dose of 10 × 106 CD34+ cells per kg body weight within a  range of 20 x 106 to 
270 × 106 TNC per kg body weight will be administered.  
2. The remaining and entire CD34-depleted fraction derived from the same UCB unit as the 
ex vivo expanded CD34+ cells (the CD34- depleted fraction). All available CD34 -negative 
cells will be  administered.  
The MGTA-456 production process results  in a median >80 0-fold TNC expansion and a median  
>300-fold CD34+ cell expansion. The absolute number of CD34+ cells in the final product is 
affected by the number of CD34+ cells available in the starting UCB unit and the rate of differentiation of the unit during the cul ture. Due to differences between UCB units, the final  
CD34+ cell fraction  of MGTA-456 constituted  a median  of 31.5%  of all  nucleated cells  (range  of 
19.3% to 53.7%; see Ta ble 2  for a comparison of TNC required to achieve the target CD34 cell 
dose). Furthermore, the final CD34+ cell dose is also affected by the patient's body weight resulting  in a range of administered TNC  and CD34+ cell doses.  
Overcoming the engraftment barrier in IMD patients (who have not received prior immunosuppressive or cytoreductive therapy prior to transplant conditioning as is typical in oncology patients) undergoing UCBT is challenging, and historically required fully myeloablative conditioning regimens ( Prasad et al 2008; B oelens et al 2013). It is expected that 
the higher dose of CD34+ cells present in MGTA -456 compared to a conventional UCB unit will 
promote engraftment in IMD patients. The need for high doses of CD34+ cells must be balanced with potential safety  risks associated  with the  infusion of high numbers of nucleated cells.  
Therefore,  the study will target the administration of a CD34+ cell dose (targeting 10 × 10
6 
CD34+ cells per kg body weight compared to typically less than 1 × 106 CD34+ cells per kg 
body weight in a conventional UCB unit) and allow the use of up to 270 × 106 TNC/kg body 
weight in the IMD pediatric population which is the upper limit of the dosing window that has 
been  investigated and has showed a favorable safety profile in  oncology patients.  
The rationale for  selecting  the above cell doses  is based  on the following observations: 
• Higher CD34+ cell doses speed up neutrophil engraftment and establish long term 
chimerism in IMD  (Martin et  al 2006, B oelens et  al 2013). 
• MGTA-456 has shown a relationship between infused cell dose and engraftment 
(Figure 2, Investigator Brochure attached)  
• In IMD specifically, the successful use of reduced dose conditioning regimens has been  impeded  by a suboptimal engraftment ( Alde nhoven et  al 2015a). However, IMD  
patients, unlike malignancy patients, do not typically receive myelotoxic and 
immunosuppressive chemotherapy as initial therapy for malignancy prior to HSCT. Additionally, in models of IMD in mice (e.g., Hurler syndrome) the accumulation of toxic byproducts in the bone marrow leads to impaired homing of stem cells ( Watson  
et al 2014; 
Alde nhoven et al 2015a). 
• Even  with MAC,  there is a substantial risk  of graft failure.  In the COBLT  trial report  
on UCBT in IMD,  the median number of CD34+ cells was  0.2 × 106/kg (range: 0.04 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
36  
 4. POPULATION  
The study population will include pediatric patients age < 2.5 years with Hurler syndrome, age 2- 
17 years with cerebral adrenoleukodystrophy (cALD), age < 16 years with metachromatic leukodystrophy (MLD) and age ≤  10 years  with globoid cell leukodystrophy (GLD) (also  
referred to as Krabbe) Approximately 12 patients will be enrolled in the study, with the possibility  of expanding to include up to approximately 15 additional patients. 
The study will enroll pediatric patients with an IMD in whic h enzyme replacement treatment is  
not effective in preventing CNS deterioration likely due to the enzyme’s inability to cross the blood brain barrier. Furthermore, only those disorders will be included for which there is considerable published evidence eit her from registries or from single institutions demonstrating  
the efficacy of allogeneic HSCT in limiting disease progression. Therefore, we will recruit only patients with diseases and disease stages in which allogeneic HSCT is considered ‘standard’ and  
in which HSCT is considered a treatment option per International EBMT guidelines (The EBMT Handbook 2008-Chapter 41) and a recent publication ( Boelens et al 2014). Therefore, Hurler 
syndrome, c ALD, MLD,  and GLD will be  included. 
Any patient  (or guardian) withdrawing their  consent or any  patient  withdrawn  because of an 
event unrelated to the study, at any time during the study, will be replaced to ensure approximately 6 patients in each cohort.  
The patient  must meet  all inclusion criteria  before the  expansion culture will be  initiated.  
After  1 year,  patients  may  be trans ferred  to a separate long- term follow up study, if  eligible  and 
willing  (after signature  of the specific study ICF).  
4.1 Inclusion  Criteria  
Patients  must fulfill all the following criteria  to be eligible  for this study: 
1. Written  informed  consent  must be obtained from  the patient  or parent/guardian before  any 
assessment is performed. Study assents will also be prepared for children and adolescents to review  when applicable.  
2. Male and female, age < 2.5 years with Hurler syndrome, age 2 -17 years with cerebral  
adrenoleukodystrophy (cALD), age < 16 years with metachromatic leukodystrophy 
(MLD) and age ≤ 10 years  with globoid cell  leukodystrophy (GLD)  (also  referred to  as 
Krabbe)Diagnosed with 1 of the following IMD:  
a. Hurler  syndrome (mucopolysaccharidosis MPS -IH) 
b. MLD;  asymptomatic  late-infantile,  or asymptomatic/minimally  symptomatic juvenile 
onset patients 
c. GLD;  asymptomatic  infants, or asymptomatic/minimally  symptomatic  attenuated  
disease  
d. ALD; with active cerebral disease as established by radiographic review of brain MRI  
demonstrating a Loes score ≤10 and with a neurological function score (NFS) ≤1 
(Moser,  Arch Neurol 2005;62:1073-1080) 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
37  
 3. Able  to complete  all study procedures, measurements and  visits;  and parent/guardian and  
patient has adequately supportive psychosocial circumstances, in the opinion of the 
Investigator. 
4. Patient  must have a minimum life  expectancy of 6 months in the judgment of the 
Investigator. 
5. Recipients  must meet the following: 
• Lansky score ≥50%  
• Renal:  serum  creatinine ≤2.5  × upper limit  of normal (ULN)  corrected  for age  
• Hepatic:  total bilirubin  and ALT  ≤3 ×  ULN corrected  for age  
• Pulmonary function: oxygen saturation ≥92% without an oxygen requirement (an 
exception may be made as documented in the medical record for patients with  
abnormal sleep studies  [such  as patients with  Hurler  syndrome]) 
• Cardiac:  left ventricular  ejection  fraction (LVEF) ≥30%.  
6. Graft  Characteristics  
• The unrelated  UCB grafts  must be at  least  6/8 HLA -A, HLA- B, HLA -C, and 
HLA- DRB1 matched with the recipient at the allele level. This is based upon a recent  
publication which showed that allele- level matching at HLA -A, HLA- B, HLA -C and  
HLA-DRB1 between the UCB unit and its recipient is associated with best survival 
and lowest occurrence of graft failure  in children with non- malignant diseases.  
• UCB units must come from a qualified UCB bank(s) per institutional standard 
operating procedures (SOPs). A matched UCB unit from an unlicensed bank must be 
pre-approved by the sponsor before use. If the UCB unit is unlicensed (most 
commonly based on location [eg, European countries], testing by non- Clinical  
Laboratory Improvement Amendment (CLIA)-approved laboratories, or collection before 25 May 2005), Magenta will make the final decision on patient eligibility  
based  on the reason why the UCB unit is unlicensed. 
• The minimal TNC count for the selected  UCB unit is to be 1.0 × 10
7/kg body weight. 
• In a case where there is a better HLA -matched UCB unit with a lower cell dose, it 
may be selected over  a less well -matched unit with a  higher cell dose 
• The patient must not have donor specific anti HLA antibodies considering HLA A, B, 
C, DRB1, DQ and  DP (MFI  >1000). 
• A suitable back -up HSC source (UCB unit or unaffected haploidentical donor) must  
be available.  
• Cord blood grafts require genetic testing and/or demonstration of enzyme activity for patients with Hurler syndrome, MLD or GLD and are tested for very long chain fatty  
acids  (VLCFA)  to confirm there is no evidence of VLCFA  consistent with ALD.  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
38  
 4.2 Exclusion  Criteria  
Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No 
additional exclusions may be applied by the Investigator, to ensure that the study population will be representative of all eligible patients.  
1. Availability  of a HLA 8/8  matched -related donor who is not a carrier  of the same genetic  
defect.  
2. Active infection at screening (defined as requiring parenteral antibiotics because of 
persistent changes consistent with infection based on imaging studies and/or positive 
cultures) including active infection with Aspergillus or other fungus within 30 days prior to  
screening, or severe concomitant diseases which in the judgment of the Investigator would lead to the patient’s inability to tolerate conditioning regimen.  
3. Prior myeloablative  conditioning. 
4. Prior use of an  investigational study drug or procedure within  3 months before Screening  
that might confound study outcomes. Use of investigational study drugs is prohibited throughout the course of the study unless approved by Magenta. Except for approved Enzyme Replacement Therapy (ERT), use of investigational study drugs is prohibited throughout the course of the study unless approved by Magenta. 
5. Pregnant or nursing (lactating) women,  where pregnancy is defined  as the state of a female 
after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test. 
6. Females of child -bearing potential, defined as all women physiologically capable of 
becoming pregnant (including women whos e career, lifestyle, or sexual orientation  
precludes  intercourse with  a male  partner  and women  whose partner have been  sterilized  by 
vasectomy or other means), unless they are using highly effective methods of contraception 
from the day of transplant and for 1 year after infusion. Highly effective contraception 
methods include: 
• Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception). 
• Use of oral,  injected or  implanted  hormonal methods of contraception  or placement of  
an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone  
vaginal ring or transdermal hormone contraception. 
7. Sexually  active male  patients  unless they  are using condoms as contraception  starting  on 
the first day of conditioning regimen (Day -9) until 1 year after infusion or off immune suppression, whichever is last.  
8. History  of human immunodeficiency virus (HIV)  infection. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
39  
 5. TREATMENT  
5.1 Study  Treatment  
Details  on the management  of study medication, and instructions for administration  are outlined 
in the Site  Operations Manual. 
Descriptive information regarding potential treatment risks, including infusional toxicity, 
peri-infusion infection, and pre -engraftment  syndrome (PES)  may be found in  the IB. 
5.1.1 Investigational Treatment  
Starting  on Day  0 of the protocol, the day of stem  cell infusion, 2 separate therapeutic cell  
preparations will be infused sequentially in  the following order. 
1. A minimal dose of 10 × 106 CD34+ cells/kg body weight within a range of 20 x 106 to 
270 × 106 TNC/kg body weight. 
2. The entire CD34 -depleted fraction derived from the same UCB unit as the ex vivo 
expanded CD34+ cells (referred to  as the CD34 -negative fraction).  
The CD34-depleted fraction will be infused approximately one hour after the CD34+ fraction 
when all side effects relative to the CD34+ fraction have resolved, but may be infused as late as 
24 hours after  the CD34+ fraction  if adverse events  occurred  with  the expanded fraction or other  
reason  approved by the principal investigator. 
Each  patient  will be treated  only once.  A back -up HSC graft  must be available  in the event that  
the MGTA-456 product does not meet release criteria.  
 
5.1.2 Additional  Study  Treatment  
 
5.1.2.1 Conditioning  Regimen  
The dosing scheme using busulfan (BU), CY, and rabbit antithymocyte globulin (ATG) serotherapy will  be used uniformly at all clinical  sites  participating  in this study based  on 
Bartelink  et al 2008, B artelink et al  2009, B artelink et  al 2014, and P rasad  et al 2008. 
The conditioning regimen will be initiated on  Day  -9 and  will consist of:  
• BU will be administered  via IV  for 4 days (Days -9 to - 6). 
(A) Patients will receive a total of 4 doses (recommended initial dose: 120 mg/ m2 for 
age >1 year and 80 mg/m2 for age <1 year) given once daily over 3 hours and 
adjusted to achieve targeted dose range (see below). Initial dose may also be 
determined  by institutional nomogram or test dose. 
OR 
 
(B) Patients will receive a total of 16 doses (recommended initial dose 1 mg/kg) 
given every 6 hours and adjusted to achieve the targeted dose range (see below). Initial dose may also be determined by institutional nomogram or test  dose. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
40  
 • Leveteracetam (Keppra) prophylaxis against seizures will be given starting with a 
loading dose on the day  before  the first dose of BU and  continued until 24 hours after  
the final dose of BU.  
• CY will be administered via IV for 4 days (Days -5 to -2) at a dose of 50 mg/kg each  
day (total dose 200 mg/kg). Mesna prophylaxis will be administered per institutional 
protocol. The CY dose will be adjusted if the patient’s actual body weight is more 
than 125%  of the ideal  body weight (IBW). The first  dose of CY will  begin >24 hours 
after the final dose of BU.  
• ATG (rabbit; Thymoglobulin- Sanofi/Genzyme) will be administered over at least  
6 hours at 2.5 mg/kg/dose each day on Days -5 to -2. If no initial adverse reactions 
occur,  the infusion rate may be increased  per ins titutional guidelines.  
 
GVHD prophylaxis will consist of cyclosporine A (CsA) and mycophenolate mofetil (MMF). 
Pre-medications  for the conditioning regimen should be administered per Section  5.8.1. 
Table 3: Conditioning  Regimen  Scheme and GVHD  Prophylaxis 
 
Day Conditioning  Regimen  GVHD  Prophylaxis 
Day -9 BUa IV given once daily over 3 hours (A) OR q6h IV given over  
2 hours (B) -- 
Day -8 BUa IV given once daily over 3 hours (A) OR q6h IV given over  
2 hours (B) -- 
Day -7 BUa IV given once daily over 3 hours (A) OR q6h IV given over  
2 hours (B) -- 
Day -6 BUa IV given once daily  over 3 hours (A) OR q6h IV given over 
2 hours (B) -- 
Day -5 CY 50 mg/kg once daily over 1 hour + Mesna prophylaxis 
ATG once daily IV over at least 6 hoursb -- 
Day -4 CY 50 mg/kg once daily over 1 hour + Mesna prophylaxis 
ATG once daily IV over at least 6 hoursb -- 
Day -3 CY 50 mg/kg once daily over 1 hour + Mesna prophylaxis 
ATG once daily IV over at  least 6 hoursb Begin CsA and 
MMF  
Day -2 CY 50 mg/kg once daily over 1 hour + Mesna prophylaxis 
ATG once daily IV over at least 6 hoursb -- 
Day -1 -- -- 
Day 0 MGTA-456 infusion  
Day 1 -- Begin  G-CSFc 
Abbreviations: ANC=absolute neutrophil count; CY=cyclophosphamide; BU=busulfan; ATG=antithymocyte  
globulin; CsA=Cyclosporine A; MMF=mycophenolate mofetil; G -CSF= granulocyte -colony stimulating factor; 
IV=intravenous;  q6h=every  6 hours;  Css=steady state concentration  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
41  
 a BU will be targeted  to achieve cumulative  AUC  of 74 to 82 mg*h/L  (18,050  to 20,000  μM*min/L)  OR 
770 to 850 ng/mL  Css. 
b If the first dose of ATG is well tolerated,  subsequent  doses  may be administered over  a shorter  time frame  per 
institutional guidelines.  
c G-CSF will be started on  Day+1 and  continued until  the ANC  ≥2,500/μL  for 2 consecutive  days.  
 
Dosing  of BU:  
Busulfan dosing will target a cumulative AUC of 74 to 82 mg*hr/L with a goal of 
78 mg*hr/L (equivalent to 18,050 to 20,000 μM*min/L with a  goal of 
19,025 μM*min/L). 
Pharmacokinetic evaluation  of BU: 
The BU cumulative  exposure (AUC cum) goal is an AUC  range of 74 to 82 mg*hr/L with a 
target  of 78 mg*hr/L for dose adjustments. This is equivalent to 18,050 to 
20,000 μM*min/L  with  a goal of 19,025 μM*min/L. 
The BU daily ex posure goal is an  AUC range  18 to 20 mg*hr/L with a goal of 
19 mg*hr/L. This is equivalent to approximately 4500 to 5000 μM*min/L with a goal of  
4570 μM*min/L.  
The BU single dose goal (if dosage regimen is Q6h) is an AUC range of 4.5 to 5 mg*hr/L 
with a target of 4.8 mg*hr/L. This is equivalent to approximately 1100 to  
1220 uM*min/L with a  goal of 1160 uM*min/L. 
The steady  state  concentration  (Css) goal is 770 to 850 ng/mL with  a target  of 810 ng/mL.  
(A) Once daily dosing: BU will be given IV over 3 hours and adjusted to maintain an 
AUC  target  or C ss target  as indicated  above. Recommended calculation  of the AUC  is 
performed on blood samples obtained: predose, 15 minutes, 1 hour, 3 hours, 5 hours, and 7 hours after the end of infusion. Recommended calculation of C
ss is performed  
on blood samples obtained: predose, 60 minutes, 115 minutes (5 minutes before end), 
150 minutes, 3 hours, 4 hours, 5 hours, and 6 hours (prior to next dose). Busulfan 
dose is adjusted when the predicted cumulative AUC or C ss falls outside the range. If 
possible, an  evaluation of the AUC  or C ss after dose adjustment may be performed  on 
subsequent days and used to confirm that the BU exposure is within the range. 
Busulfan PK may alternatively be calculated based on institutional guidelines, 
including the use of test doses, to achieve the specified target AUC or C ss. Initial 
starting BU doses may also be calculated according to institutional nomogram or test 
dose. 
OR 
(B) Q6h dosing: BU will be given IV over 2 hours and adjusted to achieve an AUC target 
or C ss target as indicated above. Recommended calculation of the AUC is performed  
on blood samples  obtained: predose, 15 minutes,  1 hour, 3 hours, 5 hours, and  7 hours 
after the end of infusion. Recommended calculation of C ss is performed on blood 
samples  obtained: pre  dose, 60 minutes, 115 minutes (5 minutes before end),  
150 minutes, 3 hours, 4 hours, 5 hours, 6 hours (prior to next dose). Busulfan dose is 
adjuste
d when the predicted cumulative AUC or C ss falls outside the range. If 
possible, an  evaluation of the AUC or  Css after dose adjustment may  be performed  on 
subsequent days and used to confirm that the BU exposure  is within the  range. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
42  
 Busulfan PK may alternatively be calculated based on institutional guidelines, 
including the use of test doses, to achieve the specified target AUC or C ss. Initial 
starting BU doses may also be calculated according to institutional nomogram or test 
dose. 
 
Calculations  used  for AUC/C ss conversions are as follows:  
• AUC(mg*h)/L = AUC  (μM*min)/L*  246 μg/μM  * 1 mg/1000μg * 1hr/60 min 
• Css (ng/ml) =  AUC (μM*min)/L* 246 μg/μM  * 1 hr/60 min * 1000 ng/1 μg  * 
1 L/1000 mL/(Dosing frequency) 
 
For Css calculations:  
• Dosing frequency for  single dose AUC for Q6h  dosage regimen  = 6 
• Dosing frequency  for single day AUC  for Q6h or Q24h = 24 
• Dosing frequency  for total exposure (cumulative) for  Q6h  or Q24h AUC = 96  
Dosing  of CY: 
Route of Administration: The total daily dose will be given as a 1-hour IV infusion in 5% dextrose in normal saline (D5NS). Patients should receive additional hydration with 3000 mL/m
2/day of appropriate maintenance IV fluids starting 10 hours prior to CY and 
continued until 24 hours after the final  dose. Patients will  also receive mesna prophylaxis 
per institutional guidelines.  
Dose  Adjustment: Adjustment of the dose is required  if the actual  body weight (ABW)  
is more than 125% of the IBW for the age and gender. The dose should be calculated using adjusted ideal body weight (AIBW): 
IBW  Formula: 
Less than  60 inches:  
• IBW = (ht
2 × 1.65)/1000 where ht = cm, IBW = kg 
More  than 60 inches 
• Males  IBW  = 39.0 + [2.27 × (ht – 60)] where  ht = inches,  IBW  = kg 
• Females  IBW  = 42.2 + [2.27 × (ht  – 60)] where ht = inches,  IBW  = kg 
AIBW  Formula: 
• AIBW  = IBW + [(0.25) ×  (ABW  - IBW)]  
Immunosuppression:  
All patients  will receive the immunosuppression regimen  per the study treatment  plan  as 
described  below: 
• CsA: Initiate on Day - 3. A dminister per institutional guidelines with adjustment to  
maintain target serum trough levels of 200 to 400 ng/ml. Cyclosporine A weaning  
begins at Day  270 if the patient  is stably  engrafted and  has no active GVHD.  The 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
44  
 5.7.1 Slow Engraftment/Graft Failure  
The clinical management of slow engraftment/graft failure will be per institutional guidelines.  
Management of slow engraftment is triggered by the assessment of peripheral blood and bone 
marrow on Day 21. If at Day 21, the ANC is ≤0.5 × 109/L and bone marr ow cellularity is ≤5%, 
G-CSF dose may be doubled or granulocyte macrophage-colony stimulating factor (GM- CSF)  
may be added at 250 mcg/m2/d, the availability of the back-up UCB unit(s) that was put on hold 
at the time of  patient enrolment is confirmed  and a Day 28 bone marrow  biopsy is scheduled. 
If on Day  28 ANC  remains  ≤0.5 × 109/L and bone marrow  cellularity  is ≤5%,  consideration will 
be given to performing a second HSC infusion using the previously identified back up source 
after some form of preconditioning per institutional standard of care. Patients will remain on - 
study for one-year unless they undergo a second HSC infusion. The pa tient will come off study  
at the time of  the second  HSC  infusion and the event will be captured  on the eCRF.  
Use of medication,  including non-drug therapies, for  slow engraftment must be recorded  on the 
eCRF.  
 
5.7.2 Anemia  
Transfusions of packed  red blood cells  are indicated  for symptomatic  management  of anemia.  An 
attempt should be made to maintain the hematocrit >24% and hemoglobin >8 g/dL. Irradiated 
(1500 to 3000 cGy) blood products will be used in accordance with the institutional standard of 
care and all red blood cell  transfusions will be recorded  in the eCRF.  
5.7.3 Thrombocytopenia 
Prophylactic platelet transfusions should be given to maintain the platelet count >10 × 109/L or  
above the level at which signs of bleeding are known to occur, whichever is greater. All aspirin containing drugs are to be avoided. The patients should receive no intramuscular injections while thrombocytopenic. Irradiated (1500 to 3000 cGy) blood products will be used in accordance with 
the institutional standard  of care and  all platelet transfusions  will be  recorded  in the eCRF.  
5.7.4 Nutrition  
All patients will be candidates for total parenteral nutrition; length of use is per institu tional 
guidelines. 
 
5.7.5 Acute Graft  Versus  Host  Disease  
Patients will be considered evaluable for aGVHD unless they are known to have autologous 
recovery or die before Day 28 without GVHD. Organ involvement will be staged using the criteria  outlined in  the A ppendix 2. Biopsy of each  organ site  at diagnosis or major  change in  
disease activity will be performed  unless clinical circumstances make it impossible.  
5.7.6 Infusional  Reaction  
MGTA-456 expanded cell product, like other blood products, may cause infusional reactions, including hemodynamic effects or acute hypersensitivity. Furthermore, the co-infusion of residual  components of the expansion culture carries theoretical attendant  risks. These 
time-limited  events  are expected to  occur  within  the first  24 hours ( Regan  et al 2010, Kha rba
 nda 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
45  
 et al 2014), and may range from mild to moderate in severity and may include gastrointestinal 
(nausea,  vomiting, diarrhea and abdominal cramps),  respiratory  (cough, dyspnea), cardiovascular  
(hypotension, hypertension, bradycardia), neurological, or dermatological (skin flushing, rash) events,  infection, and anaphylaxis ( Martín-Henao  et al 2010). 
Emergency drugs such as epinephrine, hydrocortisone, diphenhydramine, and atropine in appropriate dosages and dilutions should be available at the bedside and administered per 
institutional  guidelines. Oxygen with  nasal prongs for standby use should be present  in the room. 
5.7.7 Engraftment  Syndrome/Transfusion  Related  Acute Lung  Injury  (TRALI)  
Engraftment syndrome is a syndrome characterized by fever, fluid retention, rash and pulmonary 
infiltrates proximal to the time of neutrophil recovery after high dose conditioning and HSCT, likely mediated by activated leukocytes and proinflammatory cytokines. Treatment is supportive, including antipyretics, oxygen and diuretics, and systemic corticosteroids or therapies directed to specific proinflammatory  cytokines (e.g., IL6).  
TRALI is a rare but serious syndrome characterized by sudden acute respiratory distress 
following transfusion. It is defined as new, acute lung injury during or within six hours after blood product administration in  the absence of other risk  factors for acute lung  injury. TRALI  is 
thought to be caused by activation of recipient neutrophils by donor-derived antibodies targeting 
HLA or human neutrophil antigen (HNA), in most cases. Non-antibody- mediated cases occur  
and may be mediated by biologic response modifiers present in the transfused blood product, 
along with recipient factors. Treatment is supportive and consists of oxygen, ventilator support and management of fluid balance.  
 
5.7.8 Autoimmune  Cytopenia 
Autoimmune cytopenia is the single or combination of auto/alloimmune hemolytic anemia, idiopathic thrombocytopenic purpura, and/or autoimmune neutropenia developing after HSCT. The mechanism of AIC development is not clearly understood but is postulated to be from immune dysregulation leading to aberrant antibody production. An increased incidence of AIC has been observed in transplant for non-malignant diseases, in particular for IMDs and Hurler Syndrome with rates between 20 to 56% ( Deambrosis et al, 2018; P age et al 2008; Kha lil et al  
2014). Age at transplant is an independent risk factor for AIC with incidence in infants reported up to 56% ( Page et al 2008; Kr uizinga et al 2018). Based on an evolving understanding of AIC, 
if investigation of a cytopenia reveals a single auto -antibody towards one cell line, it is 
recommended to test for antibodies to all lineages (red cell, platelet, and neutrophil) to guide early treatment. Recommended first line trea tment is steroids, intravenous immunoglobulin 
(IVIg), and rituximab. Initiating plasmapheresis earlier in therapy is suggested to remove the auto-reactive antibody already produced. 
 
5.8 Concomitant  Treatment  
All prescription medications, over-the-counter drugs and significant non-drug therapies 
(including physical therapy and blood transfusions) administered or taken within the timeframe 
defined  in the entry criteria prior  to the start of  the study and  during the study, must be recorded  
on the eCRF.  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
46  
 Medication entries should be specific to trade name, the single dose and unit, the frequency and 
route of administration,  the start and discontinuation date and the reason  for therapy. In general,  
concomitant medications and therapies deemed necessary for the supportive care and safety of  
the patient (eg, approved enzyme replacement therapy  [ERT]) are allowed.  
5.8.1 Pre-medications  
Leveteracetam will be administered to all patients in accordance with institutional guidelines as 
seizure prophylaxis during BU therapy, starting with a loading dose on the day before the first 
dose of BU and continuing for at least 24 hours after the last dose of BU. The following pre- 
medications will be administered 30 minute s prior to each dose of ATG including: 
acetaminophen (10 mg/kg orally; maximum  dose 500 mg); diphenhydramine (1 mg/kg IV or PO; 
maximum dose 50 mg), and methylprednisolone (1 mg/kg IV; maximum dose 125 mg). Mesna will be administered per the institutional guidelines beginning prior to the first infusion of CY and continuing through at least Day -2. Anti- emetics will be administered  as needed per 
institutional  guidelines. 
Pre-medication for the MGTA -456 infusion will be per institution’s standard of care for HSC 
product infusions. 
 
5.8.2 Stem  Cell Engraftment  Enhancement  
G-CSF will be administered starting on Day +1 (5 mcg/kg IV once daily) and continued until the 
ANC ≥2,500/μl for 2 consecutive days. G -CSF is used after UCB transplantation to limit the  
duration of neutropenia (Section  5.1.2.1).  
 
5.8.3 Anti -Oxidants and Anti -Inflammatories 
Anti-oxidant and anti- inflammatory  drugs should be used  for patients  with cALD following the 
institutional  guidelines. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
47  
 6. DISCONTINUATION AND  STUDY  COMPLETION 
6.1 Discontinuation  of Study  
Patients who decide they do not wish to participate in the study further should NOT be 
considered withdrawn from the study UNLESS they withdraw their consent (see Section 6.3).  
Where possible, they should return for the asses sments listed for the final visit in Ta ble 5 . If they  
fail to return  for these  assessments,  every effort (e.g., telephone, e- mail,  letter) should  be made  to 
contact  them as specified  in Section 6.2.1. 
Patients  may  withdraw from  the study at any time.  Each  patient will be treated only  once.  
 
6.2 Study  Completion  and Post-Study  Treatment  
Each  patient  will be  encouraged to  complete  the study in its  entirety.  Study completion  is defined  
as the patient completing a 1 -year end of study visit, and any repeat assessments associated with 
this visit have been documented and followed-up appropriately by the Investigator, or in the 
event  of an  early  study termination  decisio n, the date  of that decision. Patients  will remain  
on-study for 1 year  unless they undergo a second  HSC  infusion (see Section 5.7.1).  
Following the completion  of this  study, patients  may be eligible  to participate  in a separate 
clinical  trial for  long- term safety monitoring.  
The Investigator must provide follow-up medical  care for all patients  who are  prematurely  
withdrawn  from the study, or must refer them  for appropriate ongoing care.  
6.2.1 Lost to Follow- up 
For patients whose status is unclear because they fail to appear for study visits without stating an intention  to discontinue or withdraw,  the Investigator should show due diligence by documenting 
in the source documents steps taken to contact the patient (eg, dates of telephone calls, registered letters,  etc.).  A patient  should not be formally  considered  lost to follow-up until his/her 
scheduled  end of study visit would have occurred.  
6.3 Withdrawal of Consent  
A patient  may  voluntarily withdraw consent to  participate in  the study for any reason  at any time.  
Withdrawal of consent occurs only when a patient does not want to participate in the study 
anymore, does not want any further visits or assessments and does not want any further study related  contact.  
If a patient withdraws consent, the Investigator must m ake every 
 effort to determine the primary  
reason  for this  decision  and record  this information. No further assessments  should be conducted. 
All biological material  that has  not been analyzed  at the time  of withdrawal must not be used. 
Further attempts  to contact  the patient  are not allowed  unless safety  findings require  
communicating  or follow-up. 
6.4 Study  Stopping  Rules 
If there is an indication that the use of MGTA- 456 in IMD patients is associated with an  
unacceptably  high rate of graft  failure,  TRM,  or Grade  III-IV aGVHD the study will be placed  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
48  
 on hold, available data will be  reviewed  and a decision on study continuation will be made 
jointly with the  DMC.  
The stopping rules described below will be  assessed  for Cohort 1 and 2 separately:  
• Excess  graft  failure:  graft failure  will be defined  as the absence of ANC  recovery  
>0.5 x 109/L for 3 consecutive days or lack of myeloid chimerism (<5%) by Day 42. 
The expected rate of graft failure  is approximately 15% (publi cation pending).  
Enrollment will be  stopped if 2/2, 2/3, 2/4, 2/5, or 3/6 events are observed. 
• Excess TRM by Day 100. The expected mortality rate by Day 100 after transplant is 
approximately 10% ( publication pending). Enrollment will be stopped if 2/2, 2/3, 2/4, 
2/5, or 3/6 events are observed. 
• Excess Grade III -IV acute GVHD by Day 100. The expected rate of Grade III- IV 
aGVHD is approximately 15% ( Harris et al 2018). Enrollment will be stopped if 2/2, 
2/3, 2/4, 2/5, or 3/6 events are observed. 
• One death  within 30 days of treatment,  regardless  of cohort. 
With 6 patients per cohort, the stopping rules would ensure a reasona ble probability (83%) that  
the cohort would not be stopped if the true event rate was 15% or lower while also ensuring an 
appropriate probability that the study would be stopped if the true event rate was high (66%  
probability for true event rates greater than 40%).  Enrollment will be allowed to continue while  
monitoring for safety events that would reach  a stopping rule. 
Table 4  shows some of the properties of the stopping rule for up to 10 patients (e.g., if after 
6 patients  it is decided  to continue to enroll more  patients  before  moving to  the next cohort). 
Table 4: Stopping  Rule  Properties  
 
Cohort 
Size Number of  
events 
triggeri ng 
stop Probability that 
the true rate is 
>15% given the 
data  Probability  
that the true  
rate is >10%  
given the data  Probability of  
stopping when 
true rate is 
15% Probability of  
stopping  
when true  
rate is 40% 
2 2 >99%  >99%  3% 16% 
3 2 98% >99%  6% 36% 
4 2 95% 98% 11% 53% 
5 2 92% 97% 16% 67% 
6 3 98% >99%  17% 66% 
7 3 96% 99% 17% 71% 
8 3 94% 98% 19% 76% 
9 3 92% 97% 21% 81% 
10 4 97% >99%  22% 81% 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
49  
 6.5 Early  Study  Termination  
The study may be terminated at any time for any reason by Magenta. Should this occur, patients  
who are still on study should be seen  as soon as possible and  treated  as a prematurely  withdrawn  
patient. The Investigator may be informed of additional procedures to be followed to ensure that  
adequate consideration is given to the protection of the patient’s interests.  
The Investigator will be responsible for informing institutional review boards  
(IRBs)/independent ethics  committees  (IECs)  of the early  termination  of the trial.  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
50  
 7. PROCEDURES  AND  ASSESSMENTS  
Patients should be seen for all visits on the designated day, with the assessments performed as 
per schedule, within the allowed visit /assessment window specified in the Site Operations  
Manual. However, in the event the patient cannot return to the Transplant Center on the scheduled date, every attempt will be made to obtain the required laboratory tests and shipped to the Transplant Cen ter. Patients who prematurely withdraw from the study for any reason should 
be scheduled for a visit as soon as possible, at which time all the assessments listed for the final visit will be performed. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
54  
 7.1 Informed  Consent  Procedures  
Voluntary written informed consent must be obtained before any study- related  
procedures are performed, in accordance with ICH guidelines and requirements of 
informed consent (Title 21 Code of Federal Regulations [CFR] Parts 50.20 and 50.25). Consent must be documented by the use of a written consent form  approved by Magenta 
and the site’s  IRB or IEC in accordance with  Title  21 CFR Part 50.27. 
For minor patients,  the patient’s  parent/guardian will give consent and the patient  should 
be informed about the study to the extent possible given his/her understanding. Minor 
patients capable of understanding/reading, will be given a dedicated information form to review.  
The process of obtaining informed consent should be documented in the patient source 
documents. A copy of the signed informed  consent  will be provided to the person signing 
the form, and the original will be retained  in the source  documents of the patient.  
Pregnancy  outcomes must be collected  for the female partners  of any males  administered  
study treatment  in this  study if conception occurred  within the  first week  after  
MGTA-456 administration.  Consent to report  infor mation  regarding these pregnancy 
outcomes should be obtained from the mother. 
In the event  that Magenta wants  to perform  testing  on the samples  that are not described  
in this protocol. 
A copy of the approved version  of all consent forms  must be provided to Magenta or 
designee after IRB/IEC approval. 
7.2 Patient  Demographics and Other Baseline  Characteristics  
Patient  demographic and baseline characteristic data to  be collected  on all  patients  
include date of  birth, age, sex, race, and  predominant ethnicity. 
Relevant  medical  history (including history of disease, enzyme replacement  therapy, and  
response to treatment) and current medical conditions will be recorded until the day of 
transplantation. 
Any event or change in the patient’s condition or health status occurring prior to 
MGTA-456 administration will be reported as medical history, as indicated in the 
assessment  schedule ( Table 5 ). 
 
7.2.1 Lansky  Performance Status  
Performance status will be recorded as defined by the Lansky Scale for patients less than  
16 years  of age ( Table 6 ). 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
57  
 7.4 Safety 
Safety assessments are specified in the following sections; methods for assessment and 
recording are specified in the Site Operations Manual, with Ta ble 5  detailing when each  
assessment  is to be performed.  
 
7.4.1 Physical Examination  
A complete physical examination will include the examination of general appearance, 
skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, 
lymph nodes, extremities, vascular, and nervous sys tem. If indicated based on medical  
history and/or symptoms, rectal, external genitalia, breast, and/or pelvic exams may be performed.  
Information  for all  physical examinations must be included in  the source documentation 
at the study site and will be recorded on the eCRF. Significant findings that are present prior to MGTA-456 infusion may be recorded as medical history. Significant findings observed after MGTA-456 administration which meet the definition of an AE must be appropriately recorded on the AE eCRF.  
7.4.2 Vital Signs  
Vitals signs will include body weight, body temperature, systolic and diastolic blood pressure,  pulse rate,  and pulse oximetry  will be obtained at  specified  times in  Table 5. 
 
7.4.3 Height  and Head  Circumference  
Height in centimeters will be measured at Screening and Study Day 360/EOS for all 
patients.  Head  circumference will be measured  in centimeters  at Screening  and Study 
Day 360/EOS for patients with Hurler  syndrome only. 
 
7.4.4 Laboratory Evaluations 
In the case where a laboratory assessment  that is listed in  the inclusion/exclusion criteria  
is outside of a protocol-specified range at screening and/or at the initial baseline, the 
assessment may be repeated prior to treatment number assignment. If the repeat value(s)  
remain  outside of protocol- specified ranges,  the patient will be  excluded  from  the study. 
Clinically  relevant  deviations of laboratory test  results  should be evaluated  for criteria  
defining an AE  and reported as such. 
Guidance on maximum blood volume to be collected during the study are based on the 
recommendations of the USC/LA Children’s Hospital (World Health Organization [WHO] – Bulletin of WHO; Howie 2011) on blood volumes in child health research (review  of safe limits)  and WHO  child  growth standards. The estimated blood volume for 
safety and standard of care assessments are based on standard of care laboratory assessments obtained at the site.  The recommended maximum daily blood volume is  
2 mL/kg/day. Considering the above recommendations, prioritization of sample 
collection will be needed in the pediatric population based on blood volume. Among 
protocol mandated  research -related  blood collections,  only PK samples  will be required  
to be collected on  Day 0, because they are considered relevant for patient  safety. The 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
58  
 remaining study specific samples will be prioritized as follows (highest priority first) and  
only be collected if considered to be safe by the Investigator: chimerism (CD3 T cell and 
CD33/66 [or CD15] myeloid chimerism, followed by CD19 and CD56), immune reconstitution, T cell repertoire, PK, and optional plasma biomarkers. Sample must be drawn prior to initiating conditioning regimen Lower priority research- related samples  
may be collected on a subsequent day as blood volume limitations permit (for details, refer to Appe ndix 1).  
 
7.4.4.1 Hematology 
Hemoglobin, hematocrit,  red blood cell count, white  blood cell count with  differential,  
platelet  count, and ANC will be  measured.  
7.4.4.2 Clinical Chemistry  
Sodium, potassium, bicarbonate, phosphate, creatinine, uric acid, chloride, albumin, calcium,  alkaline  phosphatase, total bilirubin, lactate dehydrogenase (LDH),  
gamma -glutamyl transferase (GGT), aspartate aminotransferase (AST), ALT, glucose,  
and blood urea nitrogen (BUN). 
Direct  and indirect  reacting  bilirubin  should be differentiated  as clinically  indicated.  
 
7.4.4.3 Viral  Testing/Infection  Surveillance 
All patients will be screened for hepatitis B surface antigen (HBsAg), hepatitis B core  
antibody (HBcAb), hepatitis C virus (HCV), herpes simplex virus (HSV), cytomegalovirus, (CMV), Epstein-Barr virus (EBV), and human T cell lymphotropic virus 1/2 (HTLV1/2) during their pre-transplant evaluation. 
Infection Surveillance of viral reactivation by quantitative PCR will be performed as 
detailed in Ta ble 5 . Testing will include CMV, EBV, and human herpesvirus (HHV- 6) as  
deemed  appropriate base d on the standard of care  at the  Institution.  
 
7.4.5 Electrocardiogram  and Echocardiogram 
Electrocardiogram  (ECG) and echocardiogram  assessments  will be conducted as detailed  
in Ta ble 5  and clinically significant abnormalities should be evaluated for criteria  
defining an AE  and reported as such. 
 
7.4.6 Pregnancy  Testing  
For all females  of child bearing  potential,  serum  pregnancy testing  is required  at 
Screening  and end of study visit, regardless of reported reproductive status.  
7.4.7 Pulmonary  Function Tests  (PFT)  
Pulmonary function tests (PFT) for assessing lung function should be performed in all 
patients capable of doing so (about age 6 years) at screening  and Day 360/End of Study 
Visit.  Otherwise  oxygen saturation should be performed  at screening  and Day  360/End of 
Study Visit.  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
63  
 8. SAFETY  MONITORING  
8.1 Adverse  Events 
An AE is any untoward medical occurrence (ie, any unfavorable and unintended sign 
[including abnormal laboratory findings], symptom or disease) in a patient or clinical investigation patient after providing written informed consent for participation in the study. Therefore,  an AE may or may not be temporally or causally associated  with  the 
use of a medicinal (investigational) product. 
The occurrence of AEs should be sought by non-directive questioning of the patient at 
each visit during the study. Adverse events also may be detected when they are 
volunteered by the patient or family during or between visits or through physical examination, laboratory test, or other assessments.  
Abnormal laboratory values or test results constitute AEs only if they fulfill at least one of the following criteria:  
• Induce clinical  signs or symptoms 
• Are considered  clinically  significant 
• Require therapy  
Clinically significant abnormal laboratory values or test results should be identified  
through a review  of values  outside of normal ranges/clinically  notable ranges,  significant 
changes from baseline or the previous visit, or values which are considered to be non- typical in patients with underlying disease. Investigators have the responsibility for managing the safety of  individual patient and  identifying adverse events. 
AEs must  be recorded on the AE eCRF for patients that meet eligibility and enroll in the  
study. The AEs should be reported per the signs, symptoms, or diagnosis associated with them,  and accompanied by the following information: 
1.The Common Toxicity Criteria Adverse Event (CTCAE) grade (version 4.03) If 
CTCAE  grading does not exist for an AE  (and this is rare), use:  
• 1=mild,  
• 2=moderate,  
• 3=severe,  
• 4=life  threatening. 
CTCAE Grade 5 (death) is not used. Fatal AEs will be collected in other eCRFs as  
per eCRF completion guidance. There may be cases where an AE with a Grade 4  
(life-threatening) may not necessarily be a serious AE (SAE) (e.g., certain lab 
abnormalities  in th e absence of meeting other seriousness criteria).  
2. Relationship  to the study treatment  (no/yes). 
3. Duration (start  and end dates)  or if  the event is  ongoing an outcome of not 
recovered/not resolved should be reported. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
64  
 4. Whether  it constitutes  an SAE  (see Section  8.2 for definition of SAE).  
5. Action  taken  regarding  study treatment.  
All AEs  should be treated  appropriately. Treatment may  include one or more  of the 
following: 
• No action  taken  (ie, further observation only) 
• Concomitant medication  given 
• Non-drug therapy  given 
• Patient  hospitalized/patient’s  hospitalization  prolonged 
6. Outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved  with  sequelae; fatal; or unknown) 
Once an AE is detected, it should be followed until its resolution or until it is judged to be 
permanent,  and assessment  should be made at each visit (or more  frequently, if 
necessary) of any changes in severity, the suspected relationship to the study drug, the 
interventions required to treat it, and the  outcome. 
Information  about common side effects  already  known about the investigational drug can  
be found in the IB or will be communicated between IB updates in the form of 
Investigator Notifications. This information will be included in the patient informed  
consent and should be discussed with the patient  during the study as needed.  
The Investigator should also instruct each patient to report any new AE (beyond the protocol observation period) that the patient,  or the patient’s  personal  physician, believes  
might reasonably be related to study treatment. This information should be recorded in  
the Investigator’s source documents and recorded on the patient eCRF are per the instructions below; however, if the AE meets the criteria of an SAE, it must be reported to Magenta.  
 
8.1.1 Non-Serious  AE Documentation  
Given the high number of non-serious AEs experienced in the patient population being studied, recording of non-serious AEs will be handled depending on when they occur. Recording of non-serious AEs will start on Day 0, the day of MGTA-456 transplant. All non-serious AEs occurring on Day 0 through 48 hours following infusion of MGTA-456 will be recorded in the clinical database via eCRFs regardless of grade or expectedness.  
Between 48 hours after the infusion of MGTA-456 and up to Day 100, all non-serious AEs except  for frequent  and anticipate d events  related  to the HSCT  procedure itself,  will 
be recorded in the clinical database. After Day 100, non- serious AEs will be collected as  
detailed  in Table 8. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
65  
 Table 8: Collection  of Non-Serious  Adverse Events  
 
Timepoint  Criteria  
Day 0  to 
Hour 48 Record  all non-serious AEs  on patient eCRF  
Hour 48 to 
Day 100 Record all non-serious AEs on patient eCRF, except for those noted below. 
These AE are considered anticipated events that are caused by the HSCT 
procedure, primarily the preparative regimen. They are either anticipated low grade (Grade 1 or 2 per the CTCAE version 4.03) events or they are captured in 
the database separately  (eg, vital sign pages, laboratory  pages). 
The following will not  be recorded  as an AE in the clinical database:  
• All non- serious hematologic lab abnormalities AEs anticipated as part of  
the HSCT  procedure, such as out of range  absolute  neutrophil or 
absolute lymphocyte counts, thrombocytopenia,  anemia 
• Anticipated Grade 1 and 2 non-serious AEs related to the HSCT procedure including but not limited to: neutropenia, mucositis, 
gastrointestinal disorders such as vomiting, nausea, diarrhea, anorexia, 
hypertension, hypotension, electrolyte imbalance, alopeci a, fatigue, 
weight gain or loss 
The following must  be recorded  as an AE  in the clinical  database:  
• Any other  event  not meeting  the exception  criteria  above including 
 All CTCAE  Grade  3 or 4 AEs  
 Any grade CTCAE AE that, in the Investigator’s clinical 
judgment, is not an anticipated result of standard HSCT  
procedures 
 Any grade evidence for infection resulting in treatment of the  
patient  
 Any grade GVHD 
 Any evidence for malignancy  
 Any grade pre -engraftment syndrome 
 Non-serious AEs that may be anticipated, but continue after 
Day 100, should be  recorded.  
Day 100 to 
end of 
study 
(+30d) All non-SAEs will be available in source documents but only documented infections, cases  of GVHD and malignancy  will be recorded in the eCRF  
 
8.2 Serious  Adverse  Event  Reporting 
8.2.1 Definition  of a Serious  Adverse Event  
An SAE  is defined  as any appearance of or worsening of any pre -existing  undesirable 
sign(s), symptom(s) or medical conditions(s) which meets any one of the following 
criteria:  
• Is fatal  or life-threatening  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
66  
 • Results  in persistent  or significant disability/incapacity  
• Constitutes  a congenital anomaly/birth  defect  
• Requires inpatient hospitalization or prolongation of existing hospitalization, 
except:  
− Routine treatment  or monitoring of the studied indication,  not associated  
with any deterioration in condition 
− Elective or pre-planned treatment for a pre- existing condition that is  
unrelated  to the indication  under study and has not worsened  since  the 
start of study drug 
− Treatment  on an emergency  outpatient basis  for an event  not fulfilling  any 
of the definitions of a SAE given above and not resulting in hospital admission  
− Social  reasons  and respite care in the absence  of any deterioration  in the 
patient’s  general condition 
• Is medically significant (ie., defined as an event that jeopardizes the p atient or  
may require  medical or surgical intervention) 
Life-threatening in the context of an SAE refers to a reaction in which the patient was at 
risk of death at the time of the reaction; it does not refer to a reaction that hypothetically  
might have caused death  if more  severe.  
All malignant neoplasms will be assessed as serious under ‘medically significant’ if other  
seriousness criteria  are not met.  
Any suspected  transmission via  a medicinal  product of an infectious agent is  also 
considered  an SAE.  
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious, such as important medical events that might not be 
immediately life threatening or result in death or hospitalization, but might jeopardiz e the 
patient  or might require intervention to prevent one of the other outcomes listed above. 
Examples  of such  events  are intensive treatment in  an emergency  room or at  home for 
allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospitalization.  
Serious adverse events are monitored continuously and have also special reporting requirements;  see Section  8.2.2. 
8.2.2 SAE  Reporting  
Every SAE, regardless of causality, occurring starting with initiation of the conditioning 
regimen (ie, Day -9) until 30 days after the last study visit (protocol period +30d) will be collected in the clinical database and must be reported to Magenta withi n 24 hours of 
learning of its occurrence as described below. Any SAEs experienced after this should only be reported to Magenta if the Investigator suspects a causal relationship to study treatment.  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
67  
  
 
 
 Re
current episodes, complications, or progr ession of the initial SAE must be reported as  
follow-up to the original episode, regardless of when the event occurs. This report must 
be submitted within 24 hours of the Investigator receiving the follow-up information. An SAE that is considered completely unrelated to a previously reported one should be reported  separately as a new event.  
SAEs (initial and follow -up) that are recorded electronically in the electronic data capture  
system should be entered, saved and e-signed within 24 hours of awareness of the SAE or changes  to an  existing SAE. 
In addition, SAEs (initial and follow-up) must be reported to the Magenta Drug Safety 
Department within 24 hours of awareness of the SAE or changes to an existing SAE. This should be done by emailing or faxing a signed copy of the SAE Report Form using the contact details below.  
 
Follow-up information provided should describe whether the event has resolved or continues, if and how it was treated, and whether the patient continued or withdrew from study participation. Each re-occurrence, complication, or progression of the original event  should be reported  as a follow-up to that event regardless of  when it occurs.  
If the SAE is not previously documented in the IB or Package Insert (new occurrence) 
and is thought to be related to the investigational treatment, Magenta may urgently require further information from the Investigator for Health Authority reporting. Magenta 
may need to issue an Investigator Notification (IN) to inform all Investigators involved in 
any study with the same investigational treatment that this SAE  has been  repo rted. 
SUSARs will be collected and reported to the competent authorities and relevant ethics  
committees  in accordance with EU Guidance 2011/C 172/01 or as  per national regulatory 
requirements  in participating countries. 
 
8.3 Pregnancy  Reporting 
Every pregnancy occurring after the patient was administered MGTA -456 under this 
protocol and until 30 days after the patient has stopped study participation must be 
reported  to Magenta within  24 hours of learning  of its  occurrence.  The pregnancy should 
be followed to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. A pregnancy occurring after signing the informed consent and before the patient is enrolled will preclude study participation.  
Pregnancy should be recorded on a Pregnancy Report Form and reported by the Investigator to the Magenta Drug Safety Department using the contact information provided in Section 8.2.2. 

Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
68  
 If the father  received  study drug, consent to  report information  regarding pregnancy 
outcome needs to be obtained from the mother. 
Table 9  indicates the level of contraception (highly effective or effective) which is 
required during the compound clinical development in males and /or females of child 
bearing  potential.  This  recommendation is  made after consideration of the latest  available 
information on clinical data. Since the immunosuppressive regimen and other frequently used co -medications include medications with teratogenic potential, women who can 
become pregnant must be made aware of the raised risk of first trimester pregnancy loss and must be counseled about pregnancy prevention and planning. 
Table 9: Contraception  Requirements  
 
Gender  Study  Participation  Need for 
Contraception Contraception Level/Method  
WOCBP  Yes Yes Highly effective  
Male  Yes Yes Effective  
WOCBP=women  of child  bearing potential 
 
8.4 Prospective  Suicidality  Assessment  
There will be no prospective suicidality assessment. However, all SAEs relating to 
suicidal  behavior will be reviewed  by the Safety  Management Team.  
 
8.5 Early  Phase  Safety  Monitoring  
The Investigator will monitor adverse events in an ongoing manner and inform Magenta 
of any clinically relevant observations. Any required safety reviews will be made jointly 
between medically qualified personnel representing Magenta and the Investigator. Such 
evaluations may occur verbally, but the outcome and key discussion points will be summarized in writing (e -mail) and made available to both Magenta and all  
Investigator(s).  
Criteria  pertaining to  stopping the study/treatment or adapt ing the study design are 
presented above.  
When 2 or more clinical site(s) are participating in the clinical study, Magenta will advise  
the Investigator(s) at all sites in writing (e -mail) (and by telephone if possible) of any 
new, clinically relevant safet y information reported from another site during the conduct 
of the study in a timely manner. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
69  
 9. DATA  REVIEW  AND  DATABASE  MANAGEMENT  
9.1 Site Monitoring  
Before  study initiation,  at a site  initiation  visit  or at  an Investigator’s meeting,  a Magenta 
representative will review the protocol and eCRFs with the Investigators and their staff. 
During the study, the Magenta representative or field monitor will visit the site regularly  
to check the completeness of patient records, the accuracy of entr ies on the eCRFs, the 
adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study product is being stored, dispensed, and accounted for per specifications. Key study personnel must be available to assist the field monitor during these visits.  
The Investigator must maintain source documents for each patient in the study, consisting of case and visit notes (hospital or clinic medical records) containing demographic and 
medical information, laboratory data, ECGs, and the results of any other tests or assessments. All information on eCRFs must be traceable to these source documents in the patient’s file. The Investigator must also keep the original informed consent form signed by the patient (a  signed copy is given to  the patient).  
The Investigator must give the monitor access to all relevant source documents to 
confirm their consistency with the eCRF entries. Magenta monitoring standards require 
full verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of data that will be used for all  primary  and safety variables.  Additional checks  of the consistency  of the 
source data with the eCRFs are performed per the study -specific monitoring plan. No 
information  in source documents about the identity of the patients will be  disclosed.  
9.2 Data  Collection  
Designated Investigator staff will enter the data required by the protocol into the eCRFs 
using fully validated software that conforms to 21 CFR Part 11 requirements. Designated Investigator site staff will not be given access to the EDC system until they have been  
trained. Automatic validation programs check for data discrepancies and, by generating appropriate error messages,  allow  the data to  be confirmed  or corrected  before transfer  of 
the data to Magenta. The Investigator must certify that the data ent ered into the eCRFs 
are complete and accurate. After database lock, the Investigator will receive a CD -ROM  
or paper  copies of the patient  data for  archiving at the investigational site.  
Data not requiring a separate written  record  will be defined  in the Site Operations Manual  
and Assessment schedule and can be recorded directly on the eCRFs. All other data 
captured for this study will have an external originating source (either written or electronic)  with the eCRF  not being considered as  source.  
9.3 Database  Management  and Quality Control  
All data should be recorded, handled  and stored in a way  that allows  its accurate 
reporting, interpretation, and verification. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
70  
 Magenta or designee will review the data entered into the eCRFs by investiga tional staff  
for completeness and accuracy and instruct the site personnel to make any required 
corrections or additions. Queries are sent to the investigational site using an electronic data query. Designated Investigator site staff is required to respond to the query and confirm  or correct  the data.  If the electronic query system  is not used, a paper  Data Query  
Form will be faxed to the site. Site personnel will complete and sign the faxed copy and fax it back  to Magenta or designee who will  make the correction to the database.  
Concomitant medications  entered  into the database will be coded  using the WHO  Drug  
Reference List, which employs the Anatomical Therapeutic Chemical classification  
system. Medical history/current medical conditions and adverse e vents will be coded  
using the Medical dictionary  for regulatory activities  (MedDRA)  terminology. 
The occurrence of any protocol deviations will be determined. After these actions have 
been  completed and  the database has been  declared  to be complete  and accurate,  it will be 
locked  and the treatment  codes will be made available for data analysis.  
9.4 Data  Monitoring Committee  
An independent and external DMC will be instituted for this study to monitor the safety 
of patients. The membership of the DMC and the responsibilities of the DMC will be 
defined  in a separate  Data Monitoring Committee  Charter  document. The  DMC  Charter  
will include information about data flow, purpose and timing of DMC meetings, 
communication strategy, procedures for ensuring confidentiality, procedures to address conflicts  of interest and statistical monitoring  guidelines. 
Members of the committee will not otherwise be involved in the conduct of the study. Magenta personnel will support the smooth functioning of the committee.  
The DMC will assess the observed safety and clinical outcomes after the first 6 patients  
have reached Day 42 post-transplant and every approximately 6 months thereafter during the trial and will give a recommendation with respect to trial continuation. DMC  
members will be responsible for clinical interpretation of the results. At the DMC's  
discretion, more  data and/or  meetings  may be r equested  and/or the timing of  the meetings  
may be changed.  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
71  
 10. DATA  ANALYSIS  
10.1 Analysis Sets 
The full analysis set will include all patients that received MGTA -456. This analysis set 
will be used for all assessments of efficacy  and safety. 
The PK analysis  set will include all patients with  available PK  data and  no major  protocol 
deviations with re levant impact on PK data.  
The PD analysis  set will include all patients with  available PD  data and  no major  protocol 
deviations with relevant impact on PD data.  
In general, data will be presented by cohort (ie, either fresh or cryopreserved HCS835 
product) and overall. 
 
10.2 Patient  Demographics and Other Baseline  Characteristics  
All data for background and demographic variables will be listed by patient. Summary 
statistics  will be  provided. 
Relevant  medical  history, current  medical  conditions, results  of laboratory screens,  drug 
tests,  and any other relevant information will be  listed by patient.  
10.3 Treatments - Study Drug, Rescue Medication, Other  
Concomitant  Therapies,  Compliance  
MGTA-456 infusions will  be summarized as  the number of each  cell type per  kilogram 
body weight. 
Concomitant treatments will be listed and summarized by time period to distinguish more  
easily between those given as part of the conditioning regimen, those given in the first 
weeks  after transplantation, and those used at during other time periods.  
 
10.4 Analysis  of the Primary  Variable(s)  
10.4.1 Endpoints  
The primary  endpoints are provided in Section  2. 
 
10.4.2 Statistical  Model,  Hypothesis, and Methods  of Analysis 
The incidence  of each  of the primary  variables  will be determined.  The overall  incidence 
will be presented together with the associated  95%  confidence interval.  
10.4.3 Handling  of Missing  Values,  Censoring,  and Discontinuations  
All available data will contribute to analyses of primary and secondary variables. Conventions for handling missing  values,  as applicable,  will be further described  in the 
Statistical Analysis Plan. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
74  
 Figure 4 shows the probability of stopping for possible true  event  rates and  for different  
sample  sizes.  
Figure 4: Probability  of Study  Stopping  Rules  with Various  Sample  Sizes  
 

Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
75  
 11. ETHICAL CONSIDERATIONS  
11.1 Regulatory  and Ethical  Compliance  
This clinical study was designed and shall be implemented and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with  
applicable local regulations (including European Directive 2001/20/EC, US Code of Federal  Regulations Title  21, and  Japanese Ministry  of Health,  Labor, and Welfare),  and 
with the ethical principles laid down in  the Declaration of  Helsinki.  
11.2 Responsibilities of the Investigator  and IRB/IEC 
Before initiating a trial, the Investigator/institution sho uld obtain approval/favorable 
opinion from the IRB/IEC for the trial protocol, written informed consent form, consent form updates, patient recruitment procedures (e.g., advertisements) and any other written information to be provided to patients. Prior to study start, the Investigator is required to sign a protocol signature page confirming his/her agreement to conduct the study in accordance with these documents and all the instructions and procedures found in this protocol and to give access to all relevant data and records to Magenta monitors, auditors, Magenta Quality Assurance representatives, designated agents of Magenta, IRBs/IECs,  
and regulatory authorities as required. If an inspection of the clinical  site is requested  by a 
regulatory authority, the Investigator must inform Magenta immediately that this request has been made.  
For multi- center  trials,  a Coordinating Investigator will be selected  by Magenta around 
the time of Last Patient Last Visit to be a reviewer and signato ry for the clinical study 
report.  
 
11.3 Publication  of Study  Protocol  and Results  
Magenta assures that the key design elements of this protocol will be posted in a publicly accessible database such as clinicaltrials.gov. In addition, upon study completion and 
finalization of the study report the results of this trial will be either submitted for  
publication and/or posted in  a publicly accessible database of clinical  trial results.  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
76  
 12. PROTOCOL ADHERENCE  
This protocol defines the study objectives, the study procedures, and the data to be 
collected on study participants. Additional assessments required to ensure safety of 
patients  should be administered  as deemed  necessary  on a case by case basis. Under no 
circumstances should an Investigator collect additional data or conduct any additional procedures for any  research related  purpose involving any investigational drugs. 
Investigators must apply due diligence to avoid protocol deviations. If the Investigator feels  a protocol deviation would improve the conduct of the study this must  be considered  
a protocol amendment, and unless such an amendment is agreed upon by Magenta and  
approved by the IRB/IEC/REB it cannot be implemented. All significant protocol deviations will be recorded and  reported in the clinical study  report.  
12.1 Protocol  Amendments 
Any change or addition to the protocol can only be made in a written protocol 
amendment  that must be approved by Magenta,  Health  Authorities  where required, and  
the IRB/IEC prior to implementation.  
Only amendments that are intended to eliminate an apparent immediate hazard to patients  
may be implemented, provided the Health Authorities and the reviewing IRB/IEC are subsequently notified by protocol amendment. 
Notwithstanding the need for approval of formal protocol amendments, the Investigator is 
expected t o take any immediate action required for the safety of any patient included in 
this study, even if this action represents a deviation from the protocol. In such cases, the 
Clinical Leader should be informed and AE/SAE reporting requirements (Section 8) followed as appropriate.  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
77  
 13. REFERENCES 
[All references  are available upon request]  
Abraham A, Cluster A, Jacobsohn D, Delgado D, Hulbert ML, Kukadiya D, Murray L, 
Shenoy S. (2017) Unrelated Umbilical Cord Blood Trans plantation for Sickle Cell 
Disease Following Reduced  Intensity  Conditioning: Results  of a Phase I  Trial,  Biology of 
Blood and  Marrow  Transplantation, http://dx.doi.org/doi: 10.1016/j.bbmt.2017.05.027 
Aldenhoven M, Jones SA, Bonney D, et al. (2015a) Hematopoietic cell transplantation for Mucopolysaccharidosis patients  is safe and effective:  results  after  implementation  of 
International Guidelines. Biol. Blood Marrow Transplant. p.1106-119. 
Aldenhoven M, Wynn RF, Orchard PJ, et al (2015b) Long-term outcome of Hurler 
syndrome patients  after hematopoietic  cell transplantation: an international multicenter  
study. Blood p. 2164-72. 
Author pending (publication pending) Comparison of pediatric allogeneic transplant 
outcomes using myeloablative busulfan with cyclophosphamide or fludarabine – supplemental tables and figures to the manuscript by Harris et al (2018) published in Blood Adv. 
Boitano AE, et al Aryl hydrocarbon receptor antagonists promote the expansion of 
human hematopoietic stem cells. Science. 2010;329:1345–8 
Bartelink  IH, Bredius RG,  Ververs  TT, et al (2008) Once -daily  intravenous busulfan with  
therapeutic drug monitoring compared to conventional oral busulfan improves survival 
and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow  Transplant. 14(1):88-98. 
Bartelink IH, Bredius RG, Belitser SV, et al (2009) Association between busulfan 
exposure and outcome in children receiving intravenous busulfan before hematologic 
stem  cell transplantation. Biol Blood Marrow Transplant. 15(2):231-41. 
Bartelink IH, van Reij EM, Gerhardt CE, et al (2014) Fludarabine and exposure- targeted  
busulfan compares favorably with busulfan/cyclophosphamide- based regimens in  
pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol.  
Blood Marrow Transplant. p. 345-53. 
Beam  D, Poe MD, Provenzale JM,  et al (2007) Outcomes of unrelated  umbilical cord  
blood transplantation for X-linked adrenoleukodystrophy. Biol Blood Marrow 
Transplant. 13(6):665-74. 
Boelens JJ, Aldenhoven M, Purtill D, et al (2013) Outcomes of transplantation using 
various hematopoietic cell sources in children with Hurler syndrome after myeloablative 
conditioning. Blood p. 3981-7. 
Boelens  JJ, Orchard  PJ, Wynn RF (2014) Transplantation in inborn errors of metabolism: 
current  considerations and future  perspectives. Br. J. Haematol.  p. 293-303. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
78  
 Boucher AA, Miller W, Shanley R, et al. Long- term outcomes after allogeneic  
hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest 
single-institution cohort report. Orphanet J Rare Dis. 2015;10:94. Published 2015 Aug 7. Brunstein CG, Gutman JA, Weisdorf DJ, et al (2010) Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood; 116:4693. 
Cremers S, Schoemaker R, Bredius R, et al (2002) Pharmacokinetics of intravenous 
busulfan in  children  prior to  stem  cell transplantation. Br J Clin  Pharm.  53(4):386-89. 
de Lima M, McMannis J, Saliba R, et al (2008) Double Cord Blood Transplantation (CBT)  with and without Ex-Vivo  Expansion (EXP): A randomized, controlled  study. 
Blood (ASH Annual Meeting Abstracts) 2008 112: Abstract 154. 
Deambrosis D, Hum R, Hiwarkar P, et al (2018) Immune mediated cytopenias following 
cord blood transplantation for Hurler’s Syndrome: a failure of pre- transplant immu ne 
suppression. ASH Annual Meeting Abstracts. 2018:Abstract 3374. 
Delaney C, Heimfeld S, Brashem -Stein C, et al (2010) Notch- mediated expansion of  
human cord  blood progenitor cells  capable of  rapid  myeloid  reconstitution. Nat  Med;  
16:232-236. de Ru, M.H., Boelens, J.J., Das, A.M. et al. Enzyme replacement therapy and/or 
hematopoietic  stem cell transplantation at diagnosis  in patients with  
mucopolysaccharidosis type I:  results  of a European consensus procedure. Orphanet  J 
Rare Dis 6, 55 (2011). 
Duffner PK, Barczykowski A, Kay DM, Jalal K, Yan L, Abdelhalim A, Gill S, Gill AL, 
Carter R. Later onset phenotypes of Krabbe disease: results of the world-wide registry. 
Pediatr  Neurol. 2012 May;46(5):298-306. 
Eapen  M, Klein  JP, Ruggeri A,  et al (2014) I mpact  of allele -level  HLA matching  on 
outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood p. 133-40. 
Eisengart  JB, Rudser KD,  Xue  Y, et  al. Long- term outcomes of systemic  therapies  for 
Hurler  syndrome:  an international multicenter  comparison. Genet Med.  
2018;20(11):1423–1429. Engelen M, Kemp S, de Visser M, et al. X- linked adrenoleukodystrophy (X -ALD):  
clinical  presentation  and guidelines for diagnosis, follow-up and management.  Orphanet J 
Rare Dis. 2012;7:51. Published 2012 Aug 13. European School of Hematology, EBMT Handbook on Haematopoietic Stem Cell 
Transplantation (2008). 2012 revised edition. Editors: J. Apperley, E. Carreras, E. 
Gluckman, T. Masszi. Howie SRC (2011) Blood sample volumes in child health research:  review  of safe limits.  Bulletin  of the World  Health  Organization. Volume 89, 
Number 1, 46-53 
Harris AC, Boelens JJ, Ahn KW, et al (2018) Comparison of pediatric allogeneic 
transplant outcomes using myeloablative  busulfan with cyclo phosphamide or fludarabine. 
Blood Adv. 2(11):1198-1206. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
79  
 Horwitz ME, Morris A, Gasparetto C, et al (2008) Myeloablative intravenous 
busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord  blood grafts  in adult recipients.  Biol.  Blood Marrow  Transplant. p. 591-4. 
Kanda J, Kaynar L, Kanda Y, et al (2013) Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. Bone 
Marrow  Transplantation; 48:926-931. 
Khalil A, Zaidman I, Bergman R, et al (2014) Autoimmune complications after 
hematopoietic stem cell transplantation in children with  nonmalignant disorders. Sci 
World J; 2014:581657. 
Kharbanda S, Smith AR, Hutchinson SK, et al (2014) Unrelated donor allogeneic 
hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced - intensity conditioning regimen and third- party mesenchymal stromal cells. Biol 
Blood Marrow Transplant; 20:581-586. 
Konuma T., et al. Cardiovascular toxicity of cryopreserved cord blood cell infusion, Bone 
Marrow  Transplantation (2008), 41, 861-865 
Krivit W,  Sung JH,  Shapiro  EG, et al  (1995) Microglia: the effector  cell for reconstitution 
of the central nervous system following bone marrow transplantation for lysosomal and 
peroxisomal storage diseases. Cell Transplant; 4(4):385-92. 
Kruizinga MD, van Tol MJD, Bekker V, et al (2018) Risk factors, treatment, and immune 
dysregulation in autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation  in pediatric  patients. Biol Blood Marrow Transplant. 24(4):772-8. 
Kühl JS, Suarez F, Gillett GT, Hemmati PG, Snowden JA, Stadler M, Vuong GL, Aubourg P,  Köhler W,  Arnold R.  Long- term outcomes of allogeneic haematopoietic stem  
cell transplantation for adult cerebral X -linked adrenoleukodystrophy. Brain. 2017 Apr 
1;140(4):953-966. 
Kwon,  J.M., Matern,  D., Kurtzberg, J. et  al. Consensus guidelines for newborn screening,  
diagnosis and  treatment  of infa ntile Krabbe disease.  Orphanet J Rare Dis 13,  30 (2018). 
Laughlin MJ, Eapen M, Rubinstein P, et al (2004) Outcomes after transplantation of cord 
blood or bone marrow  from  unrelated  donors in adults with leukemia.  N. Engl. J. Med.  p. 
2265-75. 
Lee JH, Joo YD,  Kim  H, et al  (2013) Randomized  trial of myeloablative  conditioning 
regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J. Clin. 
Oncol. p. 701-9. 
Martin PL, Carter SL, Kernan NA, et al (2006) Results of the cord blood transplantation 
study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric  patients  with  lysosomal and  peroxisomal storage diseases.  Biol.  Blood Marrow  
Transplant. p. 184-94. 
Martín -Henao GA, Resano PM, Villegas JM, et al (2010) Adverse reactions during 
transfusion of thawed haematopoietic progenitor cells from apheresis are closely related 
to the number of granulocyte cells in  the leukapheresis product. Vox  Sang; 99(3):267-73. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
80  
 Miller WP, Rothman SM, Nascene S, et al (2011) Outcomes after allogeneic 
hematopoietic  cell transplantation  for childhood cerebral  adrenoleukodystrophy: the 
largest  single- institution  cohort report. Blood; 118(7):1971-8. 
Orchard PJ, Blazar BR, Wagner J, et al (2007) Hematopoietic cell therapy for metabolic 
disease.  J Pediatr; 151(4):340-6. 
Page KM, Mendizabal AM, Prasad VK, et al (2008) Posttransplant autoimmune hemolytic  anemia and other autoimmune cytopenias are increased in  very  young infants 
undergoing unrelated donor umbilical cord blood transplantation. Biol Blood Marrow 
Transplant; 14(10): 1108-17. 
Page KM, Stenger EO, Connelly JA, Shyr D, West T,  Wood S, Case L, Kester  M, Shim 
S, Hammond L, Hammond M, Webb C, Biffi A, Bambach B, Fatemi A, Kurtzberg J. 
Hematopoietic Stem Cell Transplantation to Treat Leukodystrophies: Clinical Practice  
Guidelines from the Hunter's Hope Leukodystrophy Care Network. Biol Blood Marrow Transplant. 2019 Dec;25(12):e363-e374. 
Park M, Lee SH, Lee YH, et al (2013) Pre-engraftment syndrome after unrelated cord 
blood transplantation: a predictor of engraftment and acute graft-versus-host disease. Biol 
Blood Marrow Transplant; 19: 640-646. 
Poe MD, Chagnon SL , Escolar ML. Early treatment is associated with improved  
cognition in Hurler syndrome. Ann Neurol. 2014 Nov;76(5):747-53. Prasad  VK, Mendizabal  A, Parikh  SH, et al (2008) Unrelated  donor umbilical cord blood 
transplantation for inherited metabolic disorders in 159 pediatric patients from a single 
center: influence of cellular composition of the graft on transplantation outcomes. Blood p. 2979-89. 
Prasad  VK, Kurtzberg  J. Transplant  outcomes in mucopolysaccharidoses.  Semin  
Hematol.  2010 Jan;47(1):59-69. 
Przepiorka D, Weisdorf D, Martin P,  et al (1995) 1994 Consensus  Conference on acute  
GVHD grading. Bone Marrow Transplantation; 15:825–828. 
Raymond GV, Aubourg P, Paker A, Escolar M, Fischer A, Blanche S, Baruchel A, Dalle  
JH, Michel  G, Prasad  V, Miller  W, Paadre S, Balser  J, Kurtzberg J,  Nascene DR,  Orchard  
PJ, Lund T. Survival and Functional Outcomes in Boys with Cerebral 
Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 Mar;25(3):538-548. 
Regan DM, Wofford JD, Wall DA (2010) Comparison of cord blood thawing methods on 
cell recovery, potency, and infusion. Transfusion; 50:2670-75. 
Rubinstein P, Carrier  C, Scaradavou  A, et al (1998) Outcomes  among 562 recipients  of 
placental -blood transplants from  unrelated donors. N.  Engl. J. Med. p. 1565-77. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
81  
 Scarpa M, Orchard PJ, Schulz A, Dickson PI, Haskins ME, Escolar ML, Giugliani R. 
Treatment of brain disease in the mucopolysaccharidoses. Mol Genet Metab. 2017 Dec;122S:25-34. 
Shu Z, S. Heimfeld, D. Gao, Hematopoietic SCT with cryopreserved grafts: adverse 
reactions  after  transplantation and cryoprotectant  removal  before  infusion, Bone  Marrow  
Transplantation (2014) 49, 469-476 
van den Broek BTA, Page K, Paviglianiti A, et al. Early and late outcomes after cord 
blood transplantation  for pediatric  patients  with inherited  leukodystrophies. Blood Adv. 
2018;2(1):49–60. 
Wagner  JE., Hematopoietic  Stem  Cell  Expansion with StemRegenin -1, Presentation  at 
American  Society of Cell  and Gene Therapy, 10- 13 May 2017, Washington, D.C. 
Wagner  JE, Brunstein CG,  Boitano AE,  DeFor  TE, McKenna D,  Sumstad  D, Blazar  BR, 
Tolar J, Chap L, Jones J, Cooke MP, Bleul CC (2016) Phase I/II Trial of StemRegnin-1 
Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand Alone Graft.  Cell Stem Cell. 18(1): 144 -155. 
Watson HA, Holley RJ, Langford-Smith KJ, et al (2014) Heparan sulfate inhibits 
hematopoietic  stem and  progenitor cell migration  and engraftment in  
mucopolysaccharidosis I.  J. Biol. Chem. p. 36194-203. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
83  
  
APPENDIX  2. DIAGNOSIS AND TREATMENT OF ACUTE GRAFT  
VERSUS  HOST DISEASE  
Patients  will be considered evaluable for aGVHD if  they  demonstrate donor cell  engraftment  and 
survive to Day  28. Organ involvement will be  staged using the criteria  outlined in  Table 10. 
Biopsy of each  organ site  at diagnosis or major  change in disease activity  will be performed  
unless clinical circumstances make it impossible.  
Table 10: Staging and  Grading  aGVHD  
 
Site Stage 
Skin  0. No rash  
1. MaculoPapular  rash < 25% of body surface area  
2. MaculoPapular  rash 25-50% of  body surface area  
3. Generalized  erythroderma 
4. Generalized  erythroderma  with bullous formation  or desquamation  
Lower  GI 0. No diarrhea [peds = <281 mL/m2] (no change from  baseline)  
1. 500-1000 cc [peds  = 281 -555 mL/m2] (3-4 loose  stools/d, not interfering  with ADL)  
2. 1001-1500 cc [peds = 556-833 mL/m2] (5-7 loose stools/d, not interfering with ADL, 
IV fluids <24 hrs)  
3. >1500 cc [peds  = >833  mL/m2] (8+ loose stools/d, interfering  with ADL, IV fluids 
>24 hours) 
4. Severe abdominal  pain, +/- ileus,  +/- frank  blood 
Upper  GI 0. No prolonged nausea or vomiting  
1. Persistent  nausea,  vomiting,  or anorexia 
Liver  0. Bilirubin  2.0 mg/dL  or less 
1. Bilirubin  2.1 - 3.0 mg/dL  
2. Bilirubin  3.1 - 6.0 mg/dL  
3. Bilirubin  6.1 - 15.0 mg/dL  
4. Bilirubin  >15.1 mg/dL 
 
Overall  GVHD  Grading  
Overall Grade Organ  Stage  
Skin  Lower  GI Upper  GI Liver  
I 1-2 0 0 0 
II 3 1 1 1 
III - 2-3 - 2-4 
IV 4 4 - - 
Treatment  
Acute GVHD treatment  may be by institutional  guidelines. The  recommended  treatment  for 
patients  demonstrating moderate or severe GVHD (Grade  II-IV) is methylprednisolone 
48 mg/m2/day or prednisone 60 mg/m2/day followed by a taper.  Patients failing  front line therapy  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
84  
  
will follow the institutional treatment algorithm. Use of investigational agents will be reviewed  
with the  Sponsor. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
85  
  
APPENDIX  3. NIH  CONSENSUS  CRITERIA  FOR  DIAGNOSIS  AND  
GRADING  OF SEVERITY  OF CHRONIC  GVHD  
Signs and  symptoms of cGVHD are presented in  Table 11. 
Table 11: Signs  and Symptoms  of Chronic  GVHD  
 
Organ or site  Diagnostic 
(Sufficient to  
establish the 
diagnosis of 
cGVHD)  Distinctive (Seen in  
cGVHD, but  
insufficient alone to  
establish a diagnosis 
of cGVHD)  Other  features  Common 
(Seen with 
both aGVHD  
and cGVHD)  
Skin Poikiloderma Depigmentation  Sweat  impairment  Erythema  
Lichen  
planus- like 
features   Ichthyosis Maculopapular 
rash 
Sclerotic  
features   Keratosis pilaris  Pruritus  
Morphea- like 
features   Hypopigmentation   
Lichen  
sclerosus -like 
features   Hyperpigmentation  
Nails   Dystrophy   
 Longitudinal ridging, 
splitting, or brittle  
features    
 Onycholysis   
 Pterygium  unguis   
 Nail loss (usually  
symmetric; affects  
most nails)†    
Scalp and body 
hair  New onset of scarring  
or nonscarring scalp 
alopecia (after 
recovery from  
chemoradiotherapy) 
Scaling, 
papulosquamous lesions Thinning scalp hair, 
typically patchy, coarse, 
or dull (not explained by 
endocrine or other  
causes)   
  Premature  gray hair  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
86  
  
 
Organ or site  Diagnostic 
(Sufficient to  
establish the 
diagnosis of 
cGVHD)  Distinctive (Seen in  
cGVHD, but  
insufficient alone to  
establish a diagnosis 
of cGVHD)  Other  features  Common 
(Seen with 
both aGVHD  
and cGVHD)  
Mouth Lichen -type 
features  Xerostomia  Gingivitis  
Hyperkeratotic 
plaques Mucocele   Mucositis 
Restriction of mouth opening from  sclerosis  Mucosal atrophy  
Pseudomembranes † 
Ulcers †  Erythema  
Pain 
Eyes   New onset dry, gritty, 
or painful  eyes‡  Photophobia  
 Cicatricial  
conjunctivitis  
Keratoconjunctivitis sicca ‡  
Confluent areas of  
punctate keratopathy Periorbital 
hyperpigmentation   
  Blepharitis (erythema of  
the eyelids  with  edema)   
Genitalia  Lichen  
planus- like 
features  Erosions†   
Vaginal 
scarring or stenosis  Fissures†    
 Ulcers†    
GI tract Esophageal  
web 
Strictures or stenosis in the 
upper to mid 
third of the  
esophagus †  Exocrine pancreatic insufficiency  Anorexia 
Nausea 
Vomiting  
Diarrhea  
   Weight  loss 
   Failure to thrive  
(infants and  
children) 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
87  
  
 
Organ or site  Diagnostic 
(Sufficient to  
establish the 
diagnosis of 
cGVHD)  Distinctive (Seen in  
cGVHD, but  
insufficient alone to  
establish a diagnosis 
of cGVHD)  Other  features  Common 
(Seen with 
both aGVHD  
and cGVHD)  
Liver     Total bilirubin, 
alkaline 
phosphatase 
>2×ULN†  
   ALT  or AST  
>2×ULN  
Lung Bronchiolitis obliterans 
diagnosed with 
lung biopsy Bronchiolitis obliterans diagnosed 
with PFTs and  
radiology‡  BOOP  
Muscles, fascia,  
joints  Fasciitis  
Joint  stiffness  
or contractures  
secondary to  
sclerosis Myositis or Polymositis  Edema  
Muscle cramps 
Arthralgia  or arthritis   
Hematopoietic  
and immune    Thrombocytopenia  
  Eosinophilia  
  Lymphopenia  
  Hypo- or 
hypergammaglobulinemi a  
  Autoantibodies (AIHA 
and ITP)   
Other    Pericardial or pleural  
effusions   
  Ascites   
  Peripheral  neuropathy  
  Nephrotic syndrome  
  Myasthenia  gravis  
  Cardiac conduction abnormality or cardiomyopathy  
aGVHD=acute graft  versus  host disease;  ALT=alanine aminotransferase;  AST=aspartate aminotransferase;  
cGVHD=chronic  graft  versus  host disease;  PFT=pulmonary function  test; ULN=upper  limit of normal  
Can be acknowledged as  part of the cGVHD symptomatology if  the diagnosis  is confirmed.  
† In all  cases, infection,  drug effects, malignancy,  or other  causes  must  be excluded.  
‡ Diag nosis  of cGVHD requires  biopsy or radiology confirmation (or Schirmer test  for eyes).  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
88  
  
The Working Group recommends that the diagnosis of cGVHD require at least 1 diagnostic 
manifestation of cGVHD or at least 1 distinctive manifestation, with the diagnosis confirmed by  
pertinent biopsy, laboratory tests, or radiology in the same or another organ. As in aGVHD,  
infection  and other causes  may confound or complicate  the differential  diagnosis of cGVHD  
(eg, nail dystrophies associated with onychomycosis, herpes simplex, or Candida albicans infections of the oral cavity; drug toxicity) and must be excluded. Diagnostic and distinctive 
manifestations of cGVHD can be found in the skin and appendages, mouth, eyes, female 
genitalia,  esophagus, lungs, and  connective tissues.  Biopsy or other testing  is always  encouraged  
and often valuable to confirm the presence of cGVHD, but it is not always feasible and is not mandatory if the patient has at least 1 of the diagnostic findings of cGVHD ( Table 11). Please 
note that an in -depth discussion of recommended terminology for histopathologic interpretation 
may be found in a forthcoming histopathology working group report. A biopsy read as “consistent with” or “unequivocal” cGVHD will be considered sufficient to establ ish the 
diagnosis of cGVHD if accompanied  by at least 1  distinctive clinical manifestation.  
Characteristics that establish the diagnosis of cGVHD might not serve as the most appropriate  
parameters for assessing the severity of cGVHD. Valid and reliable diagnostic criteria might not be sufficiently sensitive to change to be useful as treatment- response criteria. Conversely, a 
sensitive measure of cGVHD response might not necessarily serve as an appropriate diagnostic and scoring tool. 
Organ- specific Manifestations  of Chronic  GVHD  
In all cases, drug reaction, infection, recurrent or new malignancy, and other causes must be excluded. Diagnostic clinical  or laboratory features  sufficient  for the diagnosis of cGVHD are 
italicized  in the sections  below. 
Skin  
Diagnostic manifestations include poikiloderma (eg, atrophic and pigmentary changes), lichen  
planus- like eruption (eg,  erythematous/violaceous flat -topped papules or plaques with  or without 
surface  reticulations or  a silvery  or shiny appearance on direct light),  deep sclerotic features  
(eg, smooth, wax y, indurated skin “thickened  or tight skin,” caused  by deep  and diffuse  sclerosis  
over a wide area), morphea- like superficial sclerotic features (eg, localized patchy areas of  
moveable smooth or shiny skin with a leathery-like consistency, often with dyspigmentation), or 
lichen sclerosus -like lesions (eg, discrete to coalescent gray to white moveable papules or 
plaques, often with follicular plugs, with a shiny appearance and leathery consistency). Severe sclerotic features characterized by thickened, tight, and fragile skin are often associated with  
poor wound healing, inadequate lymphatic drainage, and  skin ulcers from minor trauma.  
A distinctive feature for cGVHD (not seen in aGVHD, but not sufficiently unique to be 
considered diagnostic of cGVHD) is depigmentation. However, depigmentation would contribute to the diagnosis of cGVHD in combination with  biopsy or laboratory confirmation  of 
GVHD in skin or another organ. Sweat impairment and intolerance to temperature change from  
loss of sweat glands are seen in cGVHD. Other common, nondistinctive skin manifestations found with both aGVHD and cGVHD include  erythema, maculopapular rash, and pruritus. 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
89  
  
Nails  
Dystrophy consisting of longitudinal ridging, nail  splitting  or brittleness,  onycholysis, pterygium 
unguis, and nail loss (usually symmetric and affecting most nails) are distinctive signs of 
cGVHD,  but are not sufficient for diagnosis. 
Hair  
Distinctive features of cGVHD include new scarring and nonscarring scalp alopecia (after  
recovery  from  chemotherapy  or radiotherapy) and loss of body hair. Other  characteristics  seen  
with cGVHD include premature graying, thinning, or brittleness, but these findings are not 
diagnostic. 
Mouth  
Diagnostic features of oral cGVHD include lichen planus- like changes (white lines and  
lacy-appearing  lesions of the buccal  mucosa,  tongue, palate,  or lips), hyperkeratotic plaques 
(leukoplakia), or decreased oral range of motion in patients with sclerotic features of skin 
GVHD. Distinctive features of cGVHD include xerostomia (dryness), mucoceles, mucosal atrophy, pseudomembranes, and  ulcers  (infectious pathogens such  as yeast  or herpes  virus; 
secondary  malignancy  must be excluded). Manifestations  common to  both aGVHD and  cGVHD 
include gingivitis, mucositis, erythema, and pain. 
Eyes  
Distinctive  manifestations  of cGVHD include new onset of dry, gritty,  or painful eyes;  cicatricial  
conjunctivitis; keratoconjunctivitis sicca; and confluent areas of punctate keratopathy. Other 
features include photophobia, periorbital hyperpigmentation, difficulty in opening the eyes in the morning because of mucoid secretions,  and blepharitis (erythem a of the eye lids with  edema).  
New  ocular  sicca documented by low Schirmer  test values with  a mean  value of both eyes 
≤5 mm at 5 minutes or a new onset of keratoconjunctivitis sicca by slit -lamp examination with  
mean values of 6 to 10 mm on the Schirmer test is sufficient for the diagnosis of cGVHD if 
accompanied  by distinctive manifestations in at least 1  other organ. 
Genitalia  
Diagnostic features for the genitalia include lichen planus- like features and vaginal scarring or 
stenosis (often associated  with oral GVHD).  
Gastrointestinal  Tract  
Diagnostic features for the GI tract include esophageal web, stricture , or concentric rings  
documented by endoscopy or barium contrast radiograph. Chronic GVHD may be associated 
with pancreatic exocrine insufficiency, which often improves with enzyme supplementation. Manifestations  common to  both aGVHD and cGVHD (as well  as other  causes,  such  as drug side 
effects, motility disorders, infections, or malabsorption) include anorexia, nausea, vomiting, diarrhea, weight loss, and failure to thrive. Wasting syndrome may be a manifestation of cGVHD, but is often multifactorial (eg, decreased caloric intake, poor absorption, increased resting energy expenditures, and hypercatabolism). Endoscopic findings of mucosal edema and erythema or focal erosions with histologic changes of apoptotic epithelial cells and crypt cell dropout may be seen but are not considered diagnostic of cGVHD unless the patient also  has 
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
90  
  
distinctive  features  in a non- GI system.  Patients  with  unresolved aGVHD may have more  severe  
intestinal mucosal lesions, including ulcers and mucosal sloughing. 
Liver 
Hepatic aGVHD and cGVHD typically presents as cholestasis, with increased bilirubin or 
alkaline phosphatase, but it may also present as acute hepatitis. Because of many possible alternative  diagnoses, a liver biopsy is required  to confirm  GVHD involvement of the liver.  Note  
that because of the histologic similarity between acute and chronic liver GVHD, the diagnosis of cGVHD cannot be made on the basis of liver biopsy alone, but requires a distinctive manifestation  in at least  1 other organ system. 
Lungs  
The only diagnostic manifestation of cGVHD is biopsy-proven BO . BO diagnosed via 
pulmonary function and  radiologic testing  requires  at least  1 other distinctive  manifestation  in a 
separate organ system to establish the diagnosis of cGVHD. BO is characterized by the new 
onset of an obstructive lung defect. Clinical manifestations may include dyspnea on exertion, cough, or wheezing.  Some patients  may be asymptomatic  early in  the disease  process.  
Pneumothorax, pneumomediastinum, and subcutaneous emphysema are rare and often represent 
advanced  disease.  Restrictive  pulmonary function abnormalities secondary  to advanced  sclerosis  
of the chest wall are attributable to skin GVHD. BO is clinically diagnosed when all of the following criteria  are met: 
1. Forced  expiratory volume in 1 second/forced  vital capacity  ratio  <0.7 and  forced  expiratory 
volume in 1 second <75%  of predicted. 
1. Evidence of air trapping or small airway thickening or bronchiectasis on high-resolution chest CT (with inspiratory and expiratory cuts), residual volume >120%, or pathologic  
confirmation  of constrictive bronchiolitis. 
2. Absence of infection in the respiratory tract, documented with investigations directed by 
clinical symptoms, such as radiologic studies (radiographs or CT scans) or microbiologic 
cultures (sinus aspiration, upper respiratory tract viral screen, sputum culture, or bronchoalveolar lavage).  
3. BO-organizing pneumonia not due to infections may  represent  a manifestation  of either  
aGVHD or cGVHD and is considered a common feature. 
Musculoskeletal  System  
Diagnostic features include fascial involvement often affecting  the forearms or legs and often 
associated  with  sclerosis  of the overlying skin and subcutaneous tissue.  Fascial  involvement may  
develop without overlying sclerotic changes of the skin and can result in joint stiffness or  
contractures when present near joints. Fasciitis is detected on examination by stiffness, a 
restricted range of motion (eg, often decreased dorsal wrist flexion or inability to assume a  
Buddha prayer posture), edema of the extremities with or without erythema (early sign), peau d’orange (edematous skin with prominent pores resembling the surface of an orange), or joint 
contractures (late complications). Clinical myo sitis with tender muscles and increased muscle 
enzymes is a distinctive but nondiagnostic manifestation of cGVHD. Myositis may present as 
proximal myopathy, but this complication is  rare and does not explain the frequent complaints of 
severe  cramps.  Evalua tion of myositis  involves electromyography and  measurement  of creatine  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
91  
  
phosphokinase or aldolase.  Arthralgia and  arthritis  are uncommon and  are occasionally  
associated  with the presence of autoantibodies. 
Hematopoietic and Immune  Systems  
Abnormalities are common in cGVHD, but cannot be used to establish the diagnosis of cGVHD. 
Cytopenias may result  from  stromal damage or autoimmune  processes.  Lymphopenia (≤500/μL), 
eosinophilia (≥500/μL), hypogammaglobulinemia, or hypergammaglobuli nemia may be present.  
Autoantibodies may develop with autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura. Thrombocytopenia (<100,000/μL) at the time of cGVHD diagnosis  
has been associated with  a poor prognosis. 
Other Findings  
Serositis  (pericardial  or pleural effusions or ascites),  peripheral neuropathy, myasthenia gravis, 
nephrotic syndrome, and cardiac involvement have been attributed to cGVHD, but these 
manifestations  are rare. For  these manifestations,  cGVHD is  often a diagnosis of exclusion. 
Differential  diagnosis between  acute and chronic GVHD  
The Working Group recognized  2 main  categories of  GVHD, each  with 2 subcategories  
(Table 12). The  broad category  of aGVHD includes: 
(1) classic aGVHD (maculopapular  rash,  nausea, vomiting, anorexia,  profuse diarrhea,  ileus,  or 
cholestatic hepatitis) occurring within 100 days after transplantation or donor lymphocyte infusion (DLI; without diagnostic or distinctive  signs of cGVHD); and 
(2) persistent, recurrent, or late aGVHD: features of classic aGVHD without diagnostic or 
distinctive manifestations  of cGVHD occurring beyond 100 days of transplantation  or DLI  (often  
seen after withdrawal of immune  suppression). 
The broad category  of cGVHD includes: 
(1) classic cGVHD without features characteristic of aGVHD;  and 
(2) an overlap syndrome in which features of cGVHD and aGVHD appear together. In the 
absence of histologic or clinical signs or symptoms of cGVHD, the persistence, recurrence, or 
new onset of characteristic skin, GI  tract,  or liver abnormalities  should be classified  as aGVHD 
regardless  of the time  after transplantation.  
With  appropriate stratification,  patients  with persistent,  recurrent,  or late aGVHD  or overlap 
syndrome can be included in clinical trials with patients who have  cGVHD.  
Study IMD -001 (Amendment  v08) 10/Jan/2020  
CONFIDENTIAL  
92  
  
Table 12: Categories  of Acute and Chronic  GVHD  
 
Category Time of Symptoms  
after  HCT  or DLI  Presence of Acute 
GVHD  Features  Presence of Chronic 
GVHD  Features  
Acute  GVHD 
Classic  aGVHD ≤100 days  Yes No 
Persistent, recurrent, or 
late-onset aGVHD >100 days Yes No 
Chronic GVHD 
Classic  cGVHD No time limit No Yes 
Overlap  syndrome  No time limit Yes Yes 
DLI=Donor  lymphocyte  infusion;  GVHD=graft  versus  host disease;  HCT=hematopoietic  cell transplantation  
Table 13 presents  calculations  of mild,  moderate,  and severe  global severity,  with  examples.  If 
the entire abnormality in an organ is noted to be unequivocally explained by a non- GVHD 
documented cause, that organ is not included for calculation of the global severity. If the 
abnormality in an organ is attributed to multifactorial causes (GVHD plus ot her causes) the 
scored organ will be used for calculation of the global severity regardless of the contributing causes  (no downgrading of organ severity score). 
Table 13: Calculation of Mild, Moderate, and Severe Global Severity of Chronic 
GVHD  
 
Severity  Calculation  (with  Examples)  
Mild  • 1 or 2 organs or sites  (except lung) with  score  1 
− Mild  oral symptoms,  no decrease  in oral  intake  
− Mild  dry eyes,  lubricant  eye drops ≤3x/day  
Moderate  • 3 or more organs  with score 1  
• At least  1 organ or site  with  score 2 
− 19% to 50% body surface  area  involved or superficial  sclerosis 
− Moderate dry eyes, eye  drops >3x/day or punctal plugs  
• Lung score  1 (FEV 1 60% to  79% or  dyspnea with stairs)  
Severe  • A least 1 organ or site with  score 3  
− >50%  body surface area involved 
− Deep  sclerosis,  impaired  mobility,  or ulceration  
− Severe oral symptoms with  major  limitation  in oral intake  
− Severe dry eyes affecting  ADL  
• Lung score  2 (FEV 1 40% to 59% or dyspnea walking  on flat ground)  
FEV 1=forced  expiratory  volume  in 1 second;  GVHD=graft  versus  host disease  